

# CITATION REPORT

List of articles citing

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-t

DOI: 10.1038/ajg.2015.233

American Journal of Gastroenterology, 2015, 110, 1324-38.

**Source:** <https://exaly.com/paper-pdf/62644012/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1253	Editorial: untangling symptoms from mucosal healing in UC--a note of caution for patient-reported outcomes. <b>2015</b> , 42, 1327-8		0
1252	The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. <b>2015</b> , 9, 607-16		40
1251	Optimal delivery of follow-up care after surgery for Crohn's disease: current perspectives. <b>2016</b> , 9, 237-48		3
1250	The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. <b>2016</b> , 2016, 2483261		19
1249	Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lhmann Index-Are We Finding Our Way?. <b>2016</b> , 50, 441-4		
1248	Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond?. <b>2016</b> , 10, 1257-1258		7
1247	From bench to bedside: molecular imaging in inflammatory bowel diseases. <b>2016</b> , 32, 245-50		5
1246	Accuracy of Diffusion-weighted Magnetic Resonance Colonography in Assessing Mucosal Healing and the Treatment Response in Patients with Ulcerative Colitis. <b>2017</b> , 11, 716-723		12
1245	Refining Treatment Paradigms in Inflammatory Bowel Disease: Assessing the Options for Individualized Therapy. <b>2016</b> , 3, 4-7		2
1244	The effect of increasing physical activity and/or omega-3 supplementation on fatigue in inflammatory bowel disease. <b>2016</b> , 14, 39-50		10
1243	EHealth Technologies in Inflammatory Bowel Disease: A Systematic Review. <b>2016</b> , 10, 1103-21		76
1242	Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 541-51	0.7	84
1241	Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. <b>2016</b> , 10, 1407-1416		29
1240	RDW as a Surrogate Marker for Active Crohn's Disease: Potential Utility. <b>2016</b> , 23, 1-3		1
1239	Metotrexato no es superior a placebo para inducir remisi3n libre de esteroides, pero induce remisi3n cl3nica libre de esteroides en un mayor n3mero de pacientes con colitis ulcerosa. <b>2016</b> , 15, 76-78		
1238	Practical Approaches to "Top-Down" Therapies for Crohn's Disease. <b>2016</b> , 18, 35		10
1237	Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. <b>2016</b> , 9, 548-59		13

1236	Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. <b>2016</b> , 9, 513-26		46
1235	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <b>2016</b> , 14, 1593-1601.e2		141
1234	Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. <b>2016</b> , 10, 915-27		56
1233	Endoscopic and histologic response to cyclosporine in ulcerative colitis and their impact on disease outcome: A cohort study. <b>2016</b> , 48, 734-9		0
1232	Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 997-1006	0.7	82
1231	Recent advances in the endoscopic assessment of ulcerative colitis. <b>2016</b> , 18, 116-122		1
1230	Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in Ulcerative Colitis-the ACERTIVE study. <b>2017</b> , 11, 435-444		18
1229	Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease - authors' reply. <b>2016</b> , 43, 1347-8		
1228	Biosimilar and innovator anti-Tumour Necrosis Factor (TNF) or lymphocyte trafficking blockade: Which one to select?. <b>2016</b> , 31 Suppl 1, 24-5		
1227	Treat to target-what is realistic in Australian practice today?. <b>2016</b> , 31 Suppl 1, 4-5		
1226	New models of care in IBD in changing times. <b>2016</b> , 31 Suppl 1, 40-1		2
1225	Editorial: serologic microbial associated markers to predict Crohn's disease behaviour - authors' reply. <b>2016</b> , 44, 301-2		
1224	In vitro and in vivo inhibitory activity of 6-amino-2,4,5-trimethylpyridin-3-ols against inflammatory bowel disease. <b>2016</b> , 26, 4587-4591		12
1223	Current best practice for disease activity assessment in IBD. <b>2016</b> , 13, 567-79		117
1222	Endoscopy and cross-sectional imaging for assessing Crohn's disease activity. <b>2016</b> , 18, 123-130		7
1221	Implementation of the French national consensus for the management of ulcerative colitis into clinical practice. <b>2016</b> , 48, 1405-1409		1
1220	Capsule Endoscopy and Deep Enteroscopy in Irritable Bowel Disease. <b>2016</b> , 26, 611-27		6
1219	Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease. <b>2016</b> , 7, e192		32

1218	Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. <b>2017</b> , 11, 425-434	15
1217	Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis. <b>2017</b> , 11, 460-467	8
1216	Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. <b>2017</b> , 11, S576-S585	30
1215	WFUMB Position Paper. Learning Gastrointestinal Ultrasound: Theory and Practice. <b>2016</b> , 42, 2732-2742	28
1214	New and Evolving Immunotherapy in Inflammatory Bowel Disease. <b>2016</b> , 1, 85-95	11
1213	Introduction. <b>2016</b> , 31 Suppl 1, 23	
1212	Ultrasonographic Changes at 12 Weeks of Anti-TNF Drugs Predict 1-year Sonographic Response and Clinical Outcome in Crohn's Disease: A Multicenter Study. <b>2016</b> , 22, 2465-73	41
1211	Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. <b>2016</b> , 22, 2280-8	29
1210	Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. <b>2016</b> , 10, 1385-1394	74
1209	Evolving roles of cross-sectional imaging in Crohn's disease. <b>2016</b> , 48, 975-83	7
1208	Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. <b>2016</b> , 65, 408-14	225
1207	Preventing Collateral Damage in Crohn's Disease: The Lhann Index. <b>2016</b> , 10, 495-500	15
1206	Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. <b>2016</b> , 18, 5	19
1205	The Concept of Mucosal Healing in Ulcerative Colitis: Time and Reasons for a Reappraisal. <b>2016</b> , 10, 3-4	3
1204	Evidence for Life Before Inflammatory Bowel Disease. <b>2016</b> , 14, 825-828	5
1203	Treat to Target in Inflammatory Bowel Disease. <b>2016</b> , 14, 61-72	26
1202	Mechanism of Action of Anti-TNF Therapy in Inflammatory Bowel Disease. <b>2016</b> , 10, 989-97	152
1201	Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. <b>2016</b> , 14, 1245-1255.e8	158

1200	Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments. <b>2016</b> , 12, 741-9		1
1199	The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. <b>2016</b> , 10, 525-31		55
1198	Development and validation of the Nancy histological index for UC. <b>2017</b> , 66, 43-49		196
1197	Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort. <b>2017</b> , 49, 397-404		14
1196	Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. <b>2017</b> , 49, 280-285		10
1195	Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1584-1592	0.7	26
1194	Ultrasound-Mediated Delivery of RNA to Colonic Mucosa of Live Mice. <b>2017</b> , 152, 1151-1160		35
1193	Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. <b>2017</b> , 8, 183-188		4
1192	Structural bowel damage in quiescent Crohn's disease. <b>2017</b> , 49, 490-494		12
1191	Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. <b>2017</b> , 42, 1068-1086		15
1190	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <b>2017</b> , 66, 1049-1059		203
1189	Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC. <b>2017</b> , 66, 2063-2068		72
1188	Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. <b>2017</b> , 239, 115-146		41
1187	Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes. <b>2017</b> , 15, 1557-1564.e1		108
1186	Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. <b>2017</b> , 45, 1058-1072		35
1185	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. <b>2017</b> , 45, 1232-1243		101
1184	Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. <b>2017</b> , 15, 116-125		23
1183	Targeting interleukin 23 for Crohn's disease: finding the right drug for the right patient. <b>2017</b> , 389, 1671-1672		

1182	Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. <b>2017</b> , 129, 538-553	15
1181	Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. <b>2017</b> , 23, 894-902	78
1180	Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. <b>2017</b> , 23, 882-893	44
1179	Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. <b>2017</b> , 5, 702-707	21
1178	Transmural Healing Is Associated with Improved Long-term Outcomes of Patients with Crohn's Disease. <b>2017</b> , 23, 1403-1409	82
1177	Defining success in treating patients with inflammatory bowel disease. <b>2017</b> , 13, 645-647	3
1176	Ulcerative colitis. <b>2017</b> , 389, 1756-1770	1146
1175	Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease. <b>2017</b> , 13, 793-801	4
1174	Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. <b>2017</b> , 23, 1605-1613	21
1173	Diagnosis and management of inflammatory bowel disease in children. <b>2017</b> , 357, j2083	49
1172	Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease. <b>2017</b> , 23, 858-865	18
1171	The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease. <b>2017</b> , 23, 181-191	22
1170	Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis. <b>2017</b> , 23, 1600-1604	47
1169	Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients. <b>2017</b> , 49, 991-996	22
1168	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <b>2017</b> , 46, 310-321	85
1167	Cognitive behavioural therapy for the management of inflammatory bowel disease-fatigue with a nested qualitative element: study protocol for a randomised controlled trial. <b>2017</b> , 18, 213	10
1166	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <b>2017</b> , 7, e016146	26
1165	Calprotectin in Daily Practice: Where Do We Stand in 2017?. <b>2017</b> , 95, 293-301	33

1164	The safety of non-biological treatments in Ulcerative Colitis. <b>2017</b> , 16, 779-789		17
1163	Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. <b>2017</b> , 11, 1085-1089		41
1162	Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. <b>2017</b> , 34, 1556-1563		10
1161	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. <b>2017</b> , 23, 833-839		59
1160	Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA-UC study. <b>2017</b> , 32, 1818-1824		11
1159	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. <b>2017</b> , 45, 1291-1302		160
1158	Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?. <b>2017</b> , 45, 1274-1275		
1157	Dynamic Contrast-Enhanced Magnetic Resonance Enterography and Dynamic Contrast-Enhanced Ultrasonography in Crohn's Disease: An Observational Comparison Study. <b>2017</b> , 3, E13-E24		10
1156	Evaluation of Quality of Life in Crohn's Disease and Ulcerative Colitis: What Is Health-Related Quality of Life?. <b>2017</b> , 279-289		1
1155	Development and reliability of the new endoscopic virtual chromoendoscopy score: the PICaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ulcerative colitis. <b>2017</b> , 86, 1118-1127.e5		35
1154	Objective Assessment of Endoscopic Disease Activity and Mucosal Healing. <b>2017</b> , 267-277		2
1153	Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 325-336	0.7	85
1152	French national consensus clinical guidelines for the management of Crohn's disease. <b>2017</b> , 49, 368-377		13
1151	Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms. <b>2017</b> , 152, 309-312		48
1150	Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. <b>2017</b> , 389, 266-275		263
1149	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <b>2017</b> , 390, 2779-2789		403
1148	Targeting Crohn's disease. <b>2017</b> , 390, 2742-2744		
1147	Editorial: Endoscopic Scoring Systems in Crohn's Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment?. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1593-1595	0.7	1

1146	Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease. <b>2017</b> , 37, 65-71	9
1145	Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up. <b>2017</b> , 62, 3131-3137	6
1144	Clinical, endoscopic and histological correlation and measures of association in ulcerative colitis. <b>2017</b> , 18, 634-641	10
1143	Magnetic resonance index of activity (MaRIA) and Clermont score are highly and equally effective MRI indices in detecting mucosal healing in Crohn's disease. <b>2017</b> , 49, 1211-1217	32
1142	Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis. <b>2017</b> , 23, 2238-2244	27
1141	Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis. <b>2017</b> , 7, 13012	6
1140	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <b>2017</b> , 46, 1037-1053	165
1139	Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1658-1669	0.7 23
1138	Eosinophilic esophagitis: What can we learn from Crohn's disease?. <b>2017</b> , 5, 762-772	17
1137	Is histologic remission in ulcerative colitis ready for prime time?. <b>2017</b> , 49, 1334-1335	2
1136	Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. <b>2017</b> , 33, 82-88	31
1135	Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea. <b>2017</b> , 62, 2882-2893	7
1134	[Histopathology of IBD: What clinicians do expect in 2017?]. <b>2017</b> , 37, 277-278	
1133	The Evolution of Treatment Paradigms in Crohn's Disease: Beyond Better Drugs. <b>2017</b> , 46, 661-677	7
1132	Update on Therapeutic Drug Monitoring in Crohn's Disease. <b>2017</b> , 46, 645-659	6
1131	Management of patients with inflammatory bowel disease and spondyloarthritis. <b>2017</b> , 10, 1363-1374	11
1130	The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. <b>2017</b> , 10, 749-759	21
1129	Endoscopy in inflammatory bowel disease: advances in disease management. <b>2017</b> , 86, 952-961	4



1128	Early intervention in Crohn's disease: towards disease modification trials. <b>2017</b> , 66, 2179-2187	60
1127	Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease. <b>2017</b> , 23, 1425-1433	82
1126	Communicating the benefits and risks of inflammatory bowel disease therapy to patients and families. <b>2017</b> , 29, 572-577	2
1125	Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study. <b>2017</b> , 7, 6839	7
1124	Monitoring of small bowel Crohn's disease. <b>2017</b> , 11, 1047-1058	9
1123	Reliability of EUS indices to detect inflammation in ulcerative colitis. <b>2017</b> , 86, 1079-1087	2
1122	Sequential Crohn's Ileitis, Ileosigmoidal Fistula, Segmental Sigmoid Polyposis, and Sigmoid Stricture: The Natural History. <b>2017</b> , 51, 607-610	1
1121	Elevated C-Reactive Protein in Asymptomatic Crohn's Disease Patients: Listen to the Sound of Silence. <b>2017</b> , 23, E13	1
1120	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future Directions. <b>2017</b> , 64, 1309-1326	7
1119	PiCaSSO: a predictive score for endoscopic findings in ulcerative colitis that sounds like art but is all science. <b>2017</b> , 86, 1128-1130	1
1118	The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management. <b>2017</b> , 11, 1302-1308	8
1117	Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. <b>2017</b> , 21, 531-540	5
1116	Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. <b>2017</b> , 15, 1154-1161.e1	6
1115	Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. <b>2017</b> , 152, 362-373.e3	57
1114	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. <b>2017</b> , 45, 3-13	127
1113	Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. <b>2017</b> , 45, 264-275	27
1112	Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. <b>2017</b> , 49, 29-33	5
1111	Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients. <b>2017</b> , 11, 165-174	74

1110	Anti TNF- $\alpha$ therapy for ulcerative colitis: current status and prospects for the future. <b>2017</b> , 13, 223-233	47
1109	Patient preferences for inflammatory bowel disease treatment objectives. <b>2017</b> , 49, 152-156	32
1108	Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. <b>2017</b> , 152, 351-361.e5	153
1107	Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. <b>2017</b> , 11, 53-59	50
1106	The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study. <b>2017</b> , 45, 403-416	26
1105	Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease. <b>2017</b> , 86, 1012-1014	8
1104	A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine. <b>2017</b> , 9,	16
1103	Second Korean guidelines for the management of Crohn's disease. <b>2017</b> , 15, 38-67	28
1102	Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis' endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. <b>2017</b> , 17, 110	32
1101	The Management of Inflammatory Bowel Disease in Elderly: Current Evidence and Future Perspectives. <b>2018</b> , 2, 189-199	15
1100	[Second Korean Guidelines for the Management of Crohn's Disease]. <b>2017</b> , 69, 29-54	9
1099	Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management. <b>2017</b> , 20, 14-21	16
1098	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <b>2018</b> , 15, 222-234	54
1097	Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study). <b>2018</b> , 47, 1092-1102	24
1096	Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. <b>2018</b> , 63, 1294-1301	44
1095	Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy. <b>2018</b> , 12, 644-652	16
1094	Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. <b>2018</b> , 63, 825-833	42
1093	Capsule Endoscopy Validation of the Magnetic Enterography Global Score in Patients with Established Crohn's Disease. <b>2018</b> , 12, 313-320	9

1092	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <b>2018</b> , 12, 687-694	7
1091	Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. <b>2018</b> , 24, 254-260	11
1090	Examination of the relationship between disease activity and patient-reported outcome measures in an inflammatory bowel disease cohort. <b>2018</b> , 48, 1234-1241	6
1089	What Are the Targets of Inflammatory Bowel Disease Management. <b>2018</b> , 24, 1670-1675	21
1088	A review of magnetic resonance enterography-based indices for quantification of Crohn's disease inflammation. <b>2018</b> , 11, 1756284818765956	18
1087	Is the Objective of Treatment for Crohn's Disease Mucosal or Transmural Healing?. <b>2018</b> , 16, 1037-1039	5
1086	Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply. <b>2018</b> , 47, 142-143	0
1085	Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study. <b>2018</b> , 47, 906-912	67
1084	Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. <b>2018</b> , 67, 973-985	61
1083	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <b>2018</b> , 16, 129-146	44
1082	Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. <b>2018</b> , 63, 731-737	11
1081	Inflammatory bowel disease: towards a personalized medicine. <b>2018</b> , 11, 1756283X17745029	38
1080	Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. <b>2018</b> , 24, 277-285	9
1079	Therapeutic roles of polysaccharides from Dendrobium Officinale on colitis and its underlying mechanisms. <b>2018</b> , 185, 159-168	57
1078	Predicting response after infliximab salvage in acute severe ulcerative colitis. <b>2018</b> , 33, 1347-1352	24
1077	Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. <b>2018</b> , 16, 1276-1283.e1	30
1076	Evaluation and comparison of capsule endoscopy scores for assessment of inflammatory activity of small-bowel in Crohn's disease. <b>2018</b> , 41, 245-250	12
1075	Daily hassles score associates with the somatic and psychological health of patients with Crohn's disease. <b>2018</b> , 74, 969-988	9

1074	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <b>2018</b> , 47, 485-493		61
1073	Utility of Magnetic Resonance Enterography For Small Bowel Endoscopic Healing in Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 283-294	0.7	30
1072	Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. <b>2018</b> , 57, 929-942		52
1071	Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. <b>2018</b> , 66, 920-925		16
1070	Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion. <b>2018</b> , 12, 425-431		12
1069	It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease. <b>2018</b> , 12, 509		24
1068	Narrow band imaging efficiency in evaluation of mucosal healing/relapse of ulcerative colitis. <b>2018</b> , 6, E518-E523		15
1067	Diffusion-weighted MRI in inflammatory bowel disease. <b>2018</b> , 3, 433-443		13
1066	Agreement Between Crohn's Disease Endoscopic Severity Scores Derived from Live, Video-recorded, and Central Readings. <b>2018</b> , 24, e6-e7		
1065	The use of tofacitinib in the treatment of inflammatory bowel disease. <b>2018</b> , 10, 837-849		4
1064	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <b>2018</b> , 16, 1407-1419.e22		29
1063	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <b>2018</b> , 155, 76-87		29
1062	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <b>2018</b> , 50, 734-736		2
1061	ACG Clinical Guideline: Management of Crohn's Disease in Adults. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 481-517	0.7	518
1060	Stopping Biologics in IBD-What Is the Evidence?. <b>2018</b> , 24, 725-731		15
1059	Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. <b>2018</b> , 67, 441-446		23
1058	Practical guidance on the use of faecal calprotectin. <b>2018</b> , 9, 87-91		20
1057	Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis. <b>2018</b> , 33, 226-231		7

1056	Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?. <b>2018</b> , 472, 99-110	26
1055	Therapeutic potentials of adenosine receptors agonists and antagonists in colitis; Current status and perspectives. <b>2018</b> , 233, 2733-2740	8
1054	Validity of Contrast-enhanced Ultrasonography and Dynamic Contrast-enhanced MR Enterography in the Assessment of Transmural Activity and Fibrosis in Crohn's Disease. <b>2018</b> , 12, 48-56	56
1053	Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies. <b>2018</b> , 50, 37-41	5
1052	Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. <b>2018</b> , 47, 6-15	29
1051	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <b>2018</b> , 16, 637-647.e13	27
1050	Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease. <b>2018</b> , 154, 61-64.e6	46
1049	Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies. <b>2018</b> , 12, 63-70	29
1048	Endoscopy in Inflammatory Bowel Disease: Western PerspectiveEurope. <b>2018</b> , 275-282	
1047	Population Health Management for Inflammatory Bowel Disease. <b>2018</b> , 154, 37-45	39
1046	Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. <b>2018</b> , 50, 240-246	10
1045	Quality, Safety, and Practical Considerations of Using Biologic Therapies. <b>2018</b> , 315-328	
1044	Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice. <b>2018</b> , 33, 599-607	21
1043	Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?. <b>2018</b> , 24, 2363-2372	13
1042	Treat-to-target in Crohn's disease: Will transmural healing become a therapeutic endpoint?. <b>2018</b> , 6, 501-513	13
1041	Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. <b>2018</b> , 24, 2457-2467	46
1040	Impact of red and processed meat and fibre intake on treatment outcomes among patients with chronic inflammatory diseases: protocol for a prospective cohort study of prognostic factors and personalised medicine. <b>2018</b> , 8, e018166	11
1039	Association of sleep quality and mucosal healing in patients with inflammatory bowel disease in clinical remission. <b>2018</b> , 31, 211-216	8

1038	From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. <b>2018</b> , 24, 3681-3694	79
1037	UEG Week 2018 Poster Presentations. <b>2018</b> , 6, A135	14
1036	Capsule endoscopy: Current status and role in Crohn's disease. <b>2018</b> , 10, 184-192	6
1035	The role of biologics in the treatment of patients with inflammatory bowel disease. <b>2018</b> , 79, 686-693	1
1034	Integrated Care for Crohn's Disease: A Plea for the Development of Clinical Decision Support Systems. <b>2018</b> , 12, 1499-1504	3
1033	Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. <b>2018</b> , 2018, 4195968	6
1032	The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. <b>2018</b> , 12, 1101-1108	22
1031	Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. <b>2018</b> , 12, 1079-1100	8
1030	Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. <b>2018</b> , 48, 839-851	53
1029	The emerging role of histologic disease activity assessment in ulcerative colitis. <b>2018</b> , 88, 887-898	53
1028	Evaluation of a new pan-enteric video capsule endoscopy system in patients with suspected or established inflammatory bowel disease - feasibility study. <b>2018</b> , 6, E1235-E1246	28
1027	Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. <b>2018</b> , 88, 947-955.e2	27
1026	Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD. <b>2018</b> , 2018, 7265812	6
1025	Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. <b>2018</b> , 48, 1174-1185	23
1024	Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. <b>2018</b> , 48, 1213-1231	26
1023	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <b>2018</b> , 31, 572-582	17
1022	[Monitoring Disease Activity: How and When?]. <b>2018</b> , 71, 69-73	
1021	Nonbiological therapeutic management of ulcerative colitis. <b>2018</b> , 19, 1747-1757	8

1020	Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. <b>2018</b> , 11, 1756284818769075		9
1019	Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. <b>2018</b> , 24, 2155-2164		2
1018	Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. <b>2018</b> , 11, 1756284818772786		29
1017	Evaluation and comparison of capsule endoscopy scores for assessment of inflammatory activity of small-bowel in Crohn's disease. <b>2018</b> , 41, 245-250		0
1016	JAK inhibitors: Novel developments in management of ulcerative colitis. <b>2018</b> , 32-33, 89-93		15
1015	The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease. <b>2018</b> , 24, 1619-1623		5
1014	Colorectal cancer prevention in patients with ulcerative colitis. <b>2018</b> , 32-33, 103-109		35
1013	Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. <b>2018</b> , 6, 1117-1125		33
1012	Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis. <b>2018</b> , 50, 1019-1029		12
1011	Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1345	0.7	87
1010	The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. <b>2018</b> , 53, 825-830		23
1009	Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?. <b>2018</b> , 32-33, 9-15		1
1008	Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. <b>2018</b> , 27, 649-660		13
1007	Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. <b>2018</b> , 48, 626-637		34
1006	Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. <b>2018</b> , 98, 1983-2023		104
1005	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <b>2018</b> , 155, 687-695.e10		60
1004	[Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. <b>2018</b> , 71, 61-68		3
1003	Review article: treating-to-target for inflammatory bowel disease-associated anaemia. <b>2018</b> , 48, 610-617		19



1002	Computed Tomography and Magnetic Resonance Small Bowel Enterography: Current Status and Future Trends Focusing on Crohn's Disease. <b>2018</b> , 47, 475-499	9
1001	The state of the art on treatment of Crohn's disease. <b>2018</b> , 53, 989-998	21
1000	Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. <b>2018</b> , 12, 1180-1190	16
999	Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. <b>2018</b> , 63, 3067-3073	40
998	Inflammatory Bowel Disease in the Baby to Baby Boomer: Pediatric and Elderly Onset of IBD. <b>2018</b> , 16, 289-305	6
997	Genomic characterization of colitis-associated colorectal cancer. <b>2018</b> , 16, 121	27
996	Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis. <b>2018</b> , 12, 1326-1337	18
995	Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch. <b>2018</b> , 12, 1245-1248	13
994	Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study. <b>2018</b> , 53, 930-937	1
993	Success and safety of high infliximab trough levels in inflammatory bowel disease. <b>2018</b> , 53, 940-946	27
992	Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. <b>2018</b> , 12, 1280-1287	39
991	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. <b>2018</b> , 63, 2555-2563	6
990	Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis). <b>2018</b> , 5, e000212	15
989	Which evidence for a treat to target strategy in ulcerative colitis?. <b>2018</b> , 32-33, 3-8	10
988	Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?. <b>2018</b> , 32-33, 17-25	7
987	Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database. <b>2018</b> , 18, 23	2
986	TNF- $\alpha$ inhibits SCF, ghrelin, and substance P expressions through the NF- $\kappa$ B pathway activation in interstitial cells of Cajal. <b>2018</b> , 51, e7065	9
985	Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. <b>2018</b> , 67, 414-430	37



984	Changing treatment paradigms for the management of inflammatory bowel disease. <b>2018</b> , 33, 28-35	22
983	Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. <b>2018</b> , 21, 1-11	34
982	Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?. <b>2018</b> , 5, 140	6
981	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. <b>2018</b> , 12, 1385-1391	40
980	Magnetic resonance enterography predicts the prognosis of Crohn's disease. <b>2018</b> , 16, 445-457	6
979	Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. <b>2018</b> , 66, 680-686	5
978	Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. <b>2018</b> , 12, 1151-1157	18
977	The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. <b>2018</b> , 11, 1558-1570	46
976	Synthesis and evaluation of 6-heteroaryl-amino-2,4,5-trimethylpyridin-3-ols as inhibitors of TNF- $\alpha$ -induced cell adhesion and inflammatory bowel disease. <b>2018</b> , 9, 1305-1310	6
975	The impact of biologics in surgical outcomes in ulcerative colitis. <b>2018</b> , 32-33, 79-87	15
974	An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. <b>2018</b> , 48, 347-357	75
973	Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. <b>2019</b> , 25, 156-162	18
972	Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. <b>2019</b> , 25, 163-171	5
971	Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. <b>2019</b> , 17, 130-138.e7	44
970	Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. <b>2019</b> , 49, 94-100	7
969	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <b>2019</b> , 13, 144-164	427
968	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. <b>2019</b> , 13, 273-284	132
967	Medical staff tend to underestimate the quality of life in children and adolescents with inflammatory bowel disease. <b>2019</b> , 108, 138-142	4

966	Novel Imaging Approaches in Inflammatory Bowel Diseases. <b>2019</b> , 25, 248-260	9
965	Small-Bowel Crohn Disease Treated With Anti-Tumor Necrosis Factor- $\alpha$ Therapy: MR Enterography Score Changes After 1 Year Predict Long-Term Outcomes. <b>2019</b> , 213, 1240-1246	2
964	Letter: immune checkpoint inhibitor-induced colitis-shouldn't we be checking more often?. <b>2019</b> , 50, 472-473	1
963	The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. <b>2019</b> , 8,	3
962	Is Endoscopic Remission in Ulcerative Colitis Still Good Enough?. <b>2019</b> , 25, 1729-1730	2
961	Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. <b>2019</b> , 17, 2269-2276.e4	24
960	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <b>2019</b> , 17, 1680-1713	8
959	A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. <b>2020</b> , 26, 570-580	6
958	A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 874-883	0.7 90
957	Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort. <b>2019</b> , 7, 942-954	8
956	Innovations in Oral Therapies for Inflammatory Bowel Disease. <b>2019</b> , 79, 1321-1335	30
955	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <b>2019</b> , 157, 320-348	25
954	Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. <b>2019</b> , 33, 453-468	7
953	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <b>2019</b> , 2, e35-e63	8
952	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <b>2019</b> , 2, e1-e34	14
951	The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent Regulated. <b>2019</b> , 8,	14
950	Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation. <b>2019</b> , 51, 1117-1122	5
949	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX <sup>®</sup> (Cortiment <sup>®</sup> ) for active, mild-to-moderate ulcerative colitis. <b>2019</b> , 7, 1171-1182	5

948 More pictures: better clarity or more artifact. **2019**, 90, 168

947 Therapeutics for Inflammatory Bowel Diseases in Children and Adolescents: A Focus on Biologics and an Individualized Treatment Paradigm. **2020**, 261, 363-375

2

946 Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?. **2019**, 12, 1756284819863015

12

945 Targeting mucosal healing in Crohn's disease: what the clinician needs to know. **2019**, 12, 1756284819856865

34

944 Higher Sedation Requirements Among Inflammatory Bowel Disease Patients Undergoing Colonoscopy for Disease Activity Assessment or Dysplasia Surveillance. **2019**, 1,

0

943 Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn's disease flare: a prospective cohort study. **2019**, 4, 519-528

35

942 The influence of the brain-gut axis in inflammatory bowel disease and possible implications for treatment. **2019**, 4, 632-642

66

941 The current and potential future role of capsule technology in Crohn's disease. **2019**, 4, 493-494

940 The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. **2019**, 29, 447-470

20

939 ENFERMEDAD INFLAMATORIA INTESTINAL EN PEDIATRÍA, UNA REVISIÓN. **2019**, 30, 372-382

938 LOGROS Y DESAFÍOS DEL TRATAMIENTO DE LA ENFERMEDAD INFLAMATORIA INTESTINAL EN CHILE. **2019**, 30, 344-348

937 PREVENTION OF INFLAMMATORY BOWEL DISEASE COMPLICATIONS AND RECURRENCE. **2019**, 30, 339-343

936 Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. **2020**, 26, 304-313

6

935 Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. **2020**, 26, 1225-1231

13

934 The Role of Bowel Ultrasound in Detecting Subclinical Inflammation in Pregnant Women with Crohn's Disease. **2019**, 2, 153-160

5

933 Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization. **2020**, 3, 257-265

932 Current Concepts of Pharmacotherapy in Crohn's Disease. **2019**, 35, 344-347

1

931 Popular Diet Trends for Inflammatory Bowel Diseases: Claims and Evidence. **2019**, 17, 564-576

13

930	Medical Management of Inflammatory Bowel Disease. <b>2019</b> , 99, 1223-1235	5
929	Treat to Target: A Valid Concept for Management of Polymyalgia Rheumatica and Giant Cell Arteritis?. <b>2019</b> , 45, 549-567	5
928	Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. <b>2019</b> , 14, e0223893	2
927	Recurrence of Crohn's Disease After Small Bowel Transplantation: Fact or Fiction. <b>2020</b> , 26, 21-23	1
926	Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. <b>2019</b> , 50, 1189-1194	12
925	Remicade (infliximab): 20 years of contributions to science and medicine. <b>2019</b> , 13, 139-178	36
924	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. <b>2019</b> , 17, 285-310	41
923	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <b>2019</b> , 157, 997-1006.e6	51
922	Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease. <b>2019</b> , 7, E1018-E1026	6
921	Competition for Clinical Trials in Inflammatory Bowel Diseases. <b>2019</b> , 157, 1457-1461.e2	18
920	Maneuvering Clinical Pathways for Ulcerative Colitis. <b>2019</b> , 21, 52	2
919	Ver(s)ifying the Efficacy of Vedolizumab Therapy on Mucosal Healing in Patients With Crohn's Disease. <b>2019</b> , 157, 925-927	2
918	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <b>2019</b> , 2019, 3108025	4
917	Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers. <b>2019</b> , 15, 676-681	7
916	Therapeutic targets in inflammatory bowel disease. <b>2019</b> , 30, 315-322	
915	Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. <b>2019</b> , 157, 1007-1018.e7	82
914	The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. <b>2019</b> , 58, 2091-2098	10
913	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <b>2019</b> , 157, 1032-1043.e1	31

912	Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. <b>2019</b> , 12, 1756284819869141	2
911	Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. <b>2019</b> , 36, 3079-3095	9
910	Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF- $\beta$ -stimulated gene-6 in inflammatory bowel disease models. <b>2019</b> , 10, 718	26
909	Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity. <b>2019</b> , 7, E1253-E1261	4
908	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <b>2019</b> , 68, s1-s106	557
907	Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. <b>2019</b> , 2019, 5354320	22
906	Recent advances in monoclonal antibody therapy in IBD: practical issues. <b>2019</b> , 10, 409-416	11
905	Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. <b>2019</b> , 25, 1399-1407	11
904	Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD. <b>2019</b> , 19, 361-366	6
903	Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. <b>2019</b> , 13, 970-975	26
902	Bowel Ultrasound Imaging, Protocol and Findings. <b>2019</b> , 11-34	1
901	Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates. <b>2019</b> , 13, 864-872	48
900	Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. <b>2019</b> , 54, 49-54	6
899	Mucosal Profiles of Immune Molecules Related to T Helper and Regulatory T Cells Predict Future Relapse in Patients With Quiescent Ulcerative Colitis. <b>2019</b> , 25, 1019-1027	15
898	Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. <b>2019</b> , 17, 127-145	23
897	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. <b>2019</b> , 25, 1462-1473	10
896	Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. <b>2019</b> , 19, 13	1
895	Diagnostic delay in patients with inflammatory bowel disease in Austria. <b>2019</b> , 131, 104-112	9

894	Clinical value of fecal calprotectin. <b>2019</b> , 56, 307-320	30
893	Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). <b>2019</b> , 21, 824-839	10
892	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. <b>2019</b> , 50, 40-53	29
891	Strictures in Crohn's Disease and Ulcerative Colitis: Is There a Role for the Gastroenterologist or Do We Always Need a Surgeon?. <b>2019</b> , 29, 549-562	1
890	The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet?. <b>2019</b> , 29, 437-446	3
889	Chronic Active Ulcerative Colitis. <b>2019</b> , 131-140	
888	Endoscopic scoring systems for the evaluation and monitoring of disease activity in Crohn's disease. <b>2019</b> , 38-39, 101616	2
887	Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. <b>2019</b> , 54, 707-711	7
886	Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. <b>2019</b> , 7, 741-749	10
885	"Can Magnetic Resonance Enterography (MRE) replace ileo-colonoscopy for evaluating disease activity in Crohn's disease?". <b>2019</b> , 38-39, 101621	4
884	Editorial: assessing histological disease activity in Crohn's disease-a call for standardisation of mucosal biopsy location. <b>2019</b> , 50, 103-104	0
883	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. <b>2019</b> , 17, 1655-1668.e3	116
882	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics. <b>2019</b> , 243-255	0
881	Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease. <b>2019</b> , 31, 99-108	3
880	Challenges in IBD Research: Novel Technologies. <b>2019</b> , 25, S24-S30	8
879	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. <b>2019</b> , 2, S17-S33	31
878	Evaluation of fatigue in inflammatory bowel disease - a useful tool in daily practice. <b>2019</b> , 54, 465-470	6
877	Detection and management of early stage inflammatory bowel disease: an update for clinicians. <b>2019</b> , 13, 547-555	4

876	Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. <b>2019</b> , 13, 1387-1393	9
875	Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?. <b>2019</b> , 29, 421-436	28
874	Diagnostic pathways in Crohn's disease. <b>2019</b> , 74, 578-591	1
873	Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?. <b>2019</b> , 19, 907-918	5
872	Mucosal healing in inflammatory bowel disease: Expanding horizon. <b>2019</b> , 38, 98-109	2
871	US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. <b>2019</b> , 25, 1828-1837	15
870	Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease. <b>2019</b> , 34, 2118-2125	1
869	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <b>2019</b> , 49, 1401-1409	10
868	Predicting and preventing complications in children with inflammatory bowel disease. <b>2019</b> , 8, 70-76	3
867	Clinical Parameters Correlate With Endoscopic Activity of Ulcerative Colitis: A Systematic Review. <b>2019</b> , 17, 1265-1275.e8	17
866	Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. <b>2019</b> , 34, 1296-1315	18
865	Prediction of treatment outcome and relapse in inflammatory bowel disease. <b>2019</b> , 15, 667-677	9
864	Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study. <b>2019</b> , 13, 1311-1317	65
863	Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study. <b>2019</b> , 7, E568-E575	16
862	The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application. <b>2019</b> , 25, 1277-1290	14
861	Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. <b>2019</b> , 13, 1121-1130	6
860	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <b>2019</b> , 38-39, 101602	11
859	Reply. <b>2019</b> , 17, 573-574	

858	Evolution of treatment targets in Crohn's disease. <b>2019</b> , 38-39, 101599	3
857	The Role of Biomarkers in Treatment Algorithms for Ulcerative Colitis (UC). <b>2019</b> , 25-42	
856	Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. <b>2019</b> , 13, 1105-1110	17
855	Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitis. <b>2019</b> , 44, 409-414	1
854	Faecal Calprotectin Is a Very Reliable Tool to Predict and Monitor the Risk of Relapse After Therapeutic De-escalation in Patients With Inflammatory Bowel Diseases. <b>2019</b> , 13, 1012-1024	20
853	Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. <b>2019</b> , 13, 1227-1233	5
852	Indirect comparison of vedolizumab and adalimumab for biologic-naïve patients with ulcerative colitis. <b>2019</b> , 54, 178-187	3
851	The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects. <b>2019</b> , 8, 585-594	10
850	Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. <b>2019</b> , 17, 1814-1821.e1	29
849	Therapy for Crohn's Disease. <b>2019</b> , 150-172	
848	Ulcerative Colitis. <b>2019</b> , 173-186	1
847	What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. <b>2019</b> , 38-39, 101601	5
846	Quality of Care in Patients With Inflammatory Bowel Disease. <b>2019</b> , 25, 479-489	10
845	Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"?. <b>2019</b> , 64, 3035-3037	2
844	Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. <b>2019</b> , 13, 725-734	19
843	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <b>2019</b> , 17, 2497-2505.e1	25
842	Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. <b>2019</b> , 13, 1111-1120	23
841	Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease. <b>2019</b> , 10, e00015	8



840	Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network). <b>2019</b> , 9, e030134	2
839	Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. <b>2019</b> , 51, 1652-1660	4
838	Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice. <b>2019</b> , 18, 85-91	1
837	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 733-745	22
836	Huang-Lian-Jie-Du Decoction Ameliorates Acute Ulcerative Colitis in Mice Regulating NF- $\kappa$ B and Nrf2 Signaling Pathways and Enhancing Intestinal Barrier Function. <b>2019</b> , 10, 1354	36
835	Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. <b>2019</b> , 9, 17751	4
834	Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure. <b>2019</b> , 41, 235-242	2
833	Histologic Remission in Ulcerative Colitis: Are We There Yet?. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 713-715	0.7 3
832	ACG Clinical Guideline: Ulcerative Colitis in Adults. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 384-413	458
831	Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis. <b>2019</b> , 31, 1173-1183	3
830	Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab. <b>2019</b> , 68, 841-846	7
829	Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease. <b>2019</b> , 69, 466-473	7
828	Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial. <b>2019</b> , 5, 145	12
827	Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn's disease. <b>2019</b> , 54, 312-320	14
826	Integrating Patient-Reported Outcomes Into Treat-to-Target Monitoring Algorithms. <b>2019</b> , 17, 395-396	2
825	Advanced endoscopic techniques in the assessment of inflammatory bowel disease: new technology, new era. <b>2019</b> , 68, 562-572	25
824	Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. <b>2019</b> , 64, 1622-1631	6
823	Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. <b>2019</b> , 51, 327-334	14

822	Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD. <b>2019</b> , 13, 686-692	17
821	IBDoc Canadian User Performance Evaluation. <b>2019</b> , 25, 1107-1114	4
820	Differences in the imaging of Crohn's disease patients between North America and Europe: are we ready to bridge the divide?. <b>2019</b> , 44, 1637-1643	2
819	Real-World Success of Biologic Therapy in IBD: No More Reasons to Be Anti Antibody. <b>2019</b> , 64, 614-615	1
818	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. <b>2019</b> , 19, 89-98	23
817	Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn's disease. <b>2019</b> , 89, 364-372	15
816	The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. <b>2019</b> , 13, 541-554	51
815	Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. <b>2019</b> , 13, 424-430	37
814	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <b>2019</b> , 13, 127-137	23
813	Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. <b>2019</b> , 64, 846-854	15
812	A Treat to Target Strategy Using Panenteric Capsule Endoscopy in Pediatric Patients With Crohn's Disease. <b>2019</b> , 17, 2060-2067.e1	26
811	How Can We Assess "Complete Healing" Beyond Endoscopic Remission?. <b>2019</b> , 25, e68	
810	New approaches along the IBD course: diet, tight control and stem cells. <b>2019</b> , 16, 82-84	8
809	Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?. <b>2019</b> , 13, 319-330	21
808	Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. <b>2019</b> , 51, 340-345	8
807	Can We Estimate Quality of Life in Pediatric Inflammatory Bowel Disease Patients? An Asian Multicenter Study. <b>2019</b> , 68, 45-49	5
806	The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information. <b>2019</b> , 25, 427-435	24
805	Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. <b>2019</b> , 25, 1028-1035	13

804	Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis. <b>2019</b> , 17, 411-418.e3	23
803	Do We Still Need Predictors of Disease Severity When Applying a Treat-to-Target Approach in Inflammatory Bowel Disease?. <b>2019</b> , 13, 399-400	1
802	A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. <b>2019</b> , 4, 63-70	11
801	Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. <b>2019</b> , 25, 1036-1043	15
800	Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. <b>2019</b> , 25, 937-944	16
799	Predictors of mucosal healing during induction therapy in patients with acute moderate-to-severe ulcerative colitis. <b>2019</b> , 34, 1004-1010	3
798	Current Medical Therapies for Ulcerative Colitis. <b>2019</b> , 1-15	
797	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <b>2019</b> , 17, 1673-1679.e1	13
796	Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. <b>2019</b> , 25, 803-810	17
795	Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. <b>2019</b> , 13, 374-384	20
794	Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. <b>2019</b> , 13, 172-181	17
793	Calprotectin instability may lead to undertreatment in children with IBD. <b>2020</b> , 105, 996-998	12
792	Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. <b>2020</b> , 18, 1142-1151.e10	22
791	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <b>2020</b> , 18, 620-627.e1	7
790	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <b>2020</b> , 18, 1760-1768.e1	7
789	Soluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring. <b>2020</b> , 26, 961-969	4
788	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <b>2020</b> , 18, 14-23	38
787	Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. <b>2020</b> , 3, 74-82	1

786	Management of inflammatory bowel disease in children: It is time for an individualised approach. <b>2020</b> , 56, 1677-1684	3
785	Crohn's Disease. <b>2020</b> , 739-753	
784	Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases?. <b>2020</b> , 18, 1030-1032	1
783	Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. <b>2020</b> , 20, 363-378	22
782	Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. <b>2020</b> , 14, 332-341	18
781	Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease. <b>2020</b> , 52, 281-288	8
780	Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. <b>2020</b> , 18, 1121-1132.e2	8
779	F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. <b>2020</b> , 47, 768-777	6
778	Vaccinations and Immunization Status in Pediatric Inflammatory Bowel Disease: A Multicenter Study From the Pediatric IBD Porto Group of the ESPGHAN. <b>2020</b> , 26, 1407-1414	14
777	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <b>2020</b> , 158, 515-526.e10	28
776	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <b>2020</b> , 18, 637-646.e11	46
775	Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. <b>2020</b> , 51, 347-355	23
774	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <b>2020</b> , 14, 4-22	320
773	Exclusive enteral nutrition: An optimal care pathway for use in adult patients with active Crohn's disease. <b>2020</b> , 4, 260-266	8
772	Systematic Review: Clinical Utility of Gastrointestinal Ultrasound in the Diagnosis, Assessment and Management of Patients With Ulcerative Colitis. <b>2020</b> , 14, 465-479	16
771	Ulcerative Colitis: Current and Emerging Treatment Strategies. <b>2019</b> , 9,	19
770	Mucosal gene transcription of ulcerative colitis in endoscopic remission. <b>2020</b> , 55, 139-147	4
769	Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. <b>2020</b> , 26, 1722-1729	7

768	Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. <b>2020</b> , 69, 1778-1786	36
767	Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease. <b>2020</b> , 26, 1707-1719	9
766	Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn's Disease. <b>2020</b> , 18, 2030-2037	11
765	Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. <b>2020</b> , 18, 2518-2525.e1	26
764	A User's Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. <b>2020</b> , 18, 1336-1345	6
763	How Do We Treat Inflammatory Bowel Diseases to Aim For Endoscopic Remission?. <b>2020</b> , 18, 1300-1308	11
762	New Blood Marker of Endoscopic Disease Activity-A Step Forward in Treating Crohn's Disease to Target?. <b>2020</b> , 158, 463-465	1
761	Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies. <b>2020</b> , 20, 193-203	16
760	Is there room for immunomodulators in ulcerative colitis?. <b>2020</b> , 20, 379-390	2
759	Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review. <b>2020</b> , 14, 688-693	8
758	Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge. <b>2020</b> , 4, 267-272	10
757	Point-of-care gastrointestinal ultrasound in inflammatory bowel disease: An accurate alternative for disease monitoring. <b>2020</b> , 4, 273-279	5
756	Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. <b>2020</b> , 18, 2256-2261	10
755	Editorial: better outcomes for Crohn's disease-more than just the drugs?. <b>2020</b> , 51, 167-168	
754	Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. <b>2020</b> , 14, 710-718	1
753	Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis. <b>2020</b> , 32, 17-21	1
752	De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. <b>2020</b> , 5, 63-79	21
751	Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn's Disease. <b>2020</b> , 65, 2664-2674	8

750	Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. <b>2020</b> , 18, 2510-2517.e5	20
749	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. <b>2020</b> , 18, 1309-1323.e4	17
748	Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. <b>2020</b> , 20, 151-161	2
747	Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. <b>2020</b> , 14, 694-709	54
746	Partial enteral nutrition induces clinical and endoscopic remission in active pediatric Crohn's disease: results of a prospective cohort study. <b>2020</b> , 179, 431-438	7
745	Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. <b>2020</b> , 26, 1429-1435	3
744	Anti-interleukin-23 agents for the treatment of ulcerative colitis. <b>2020</b> , 20, 399-406	16
743	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <b>2020</b> , 51, 435-445	11
742	A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). <b>2020</b> , 91, 733-745	13
741	Evolving therapeutic goals in Crohn's disease management. <b>2020</b> , 8, 133-139	5
740	Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. <b>2020</b> , 21, 81-87	4
739	Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. <b>2020</b> , 51, 637-643	15
738	Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study. <b>2020</b> , 69, 1629-1636	33
737	Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?. <b>2020</b> , 18, 15	0
736	The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. <b>2021</b> , 33, 1008-1023	3
735	Pursuing therapeutic success in Crohn's disease: A matter of definition, tools and longterm outcomes. <b>2020</b> , 18, 205873922096289	
734	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. <b>2020</b> , 159, 2013-2018.e7	3
733	Multimic features associated with mucosal healing and inflammation in paediatric Crohn's disease. <b>2020</b> , 52, 1491-1502	4

732	Assessing Severity of Disease in Patients with Ulcerative Colitis. <b>2020</b> , 49, 671-688	10
731	Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?. <b>2020</b> , 55, 17-30	10
730	Week 2020 Poster Presentations. <b>2020</b> , 8, 144-887	3
729	Clinical course of Crohn's disease in a population-based cohort in Uppsala County followed for 10 years. <b>2020</b> , 55, 1301-1307	1
728	Remote Monitoring Empowerment of Patients with IBDs during the SARS-CoV-2 Pandemic. <b>2020</b> , 8,	5
727	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <b>2021</b> , 19, 2567-2576.e9	2
726	Performance of Capsule Endoscopy and Cross-Sectional Techniques in Detecting Small Bowel Lesions in Patients with Crohn's Disease. <b>2020</b> , 2,	2
725	Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease. <b>2020</b> , 2,	
724	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <b>2021</b> , 19, 1366-1376.e2	22
723	Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity. <b>2020</b> , 32, 1106-1115	5
722	Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 1236-1245	0.7 7
721	Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?. <b>2020</b> , 14, 807-817	5
720	Multi-"Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. <b>2020</b> , 26, 1524-1532	11
719	Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. <b>2021</b> , 70, 418-426	8
718	Inhibitors of Tumoral Necrosis Factor Alpha in Inflammatory Bowel Disease. <b>2020</b> ,	
717	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. <b>2020</b> , 26, 1306-1314	22
716	Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. <b>2020</b> , 8, CD012328	1
715	What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?. <b>2020</b> , 35, 2249-2255	1



714	Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients' Response to Biological Therapy and the Need for Colectomy. <b>2021</b> , 102, 534-545	6
713	JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. <b>2020</b> , 14, S711-S712	1
712	TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. <b>2020</b> , 101 Suppl 1, 16-26	15
711	Accuracy of point-of-care intestinal ultrasound for Crohn's disease. <b>2020</b> , 23, 176-182	0
710	Infliximab plus azathioprine is more effective than azathioprine alone in achieving mucosal healing in pediatric patients with Crohn's disease. <b>2020</b> , 21, 705-710	1
709	Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease. <b>2021</b> , 19, 1835-1844.e6	7
708	Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. <b>2021</b> , 17, 1420-1425	1
707	Nonbiologic Immune Suppression in Ulcerative Colitis. <b>2020</b> , 49, 731-738	1
706	Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease. <b>2020</b> ,	7
705	Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. <b>2021</b> , 27, 1008-1016	1
704	Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. <b>2020</b> , 32, 1579-1582	4
703	Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. <b>2020</b> , 17, 702-710	19
702	Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn's Disease. <b>2021</b> , 27, 1045-1051	7
701	Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. <b>2020</b> , 52, 1563-1573	7
700	Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. <b>2021</b> , 19, 2333-2342	6
699	Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review. <b>2020</b> , 10,	13
698	Diagnostic Performance of Simultaneous [F]-FDG PET/MR for Assessing Endoscopically Active Inflammation in Patients with Ulcerative Colitis: A Prospective Study. <b>2020</b> , 9,	1
697	Fecal calprotectin: current and future perspectives for inflammatory bowel disease treatment. <b>2020</b> , 32, 1091-1098	15



696	Ulcerative colitis. <b>2020</b> , 6, 74	182
695	Ultrasensitive molecular imaging of intestinal mucosal inflammation using leukocyte-mimicking particles targeted to MAdCAM-1 in mice. <b>2020</b> , 12,	5
694	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <b>2020</b> , 9,	6
693	COVID-19: A strong call for remote medicine in inflammatory bowel disease. <b>2020</b> , 21, 597-599	3
692	Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place. <b>2020</b> , 22, 449-461	1
691	Therapiealgorithmen für die Behandlung des Morbus Crohn im klinischen Alltag. <b>2020</b> , 1, 51-64	
690	Early Intervention in Ulcerative Colitis: Ready for Prime Time?. <b>2020</b> , 9,	12
689	Are we addressing the top 10 research priorities in IBD?. <b>2021</b> , 12, 564-569	1
688	Probe-based Confocal Laser Endomicroscopy for In Vivo Assessment of Histological Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Index. <b>2021</b> , 15, 994-999	2
687	Histopathologic Parameters at Diagnosis as Early Predictors of Histologic Remission along the Course of Ulcerative Colitis. <b>2020</b> , 2020, 8891937	1
686	Lewis score on capsule endoscopy can predict the prognosis in patients with small bowel lesions of Crohn's disease. <b>2021</b> , 36, 1851-1858	3
685	Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials. <b>2020</b> ,	1
684	Indian Journal of Gastroenterology September-October 2020. <b>2020</b> , 39, 415-418	
683	Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. <b>2021</b> , 27, 1452-1461	4
682	Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. <b>2021</b> , 27, 1674-1683	3
681	A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease. <b>2020</b> , 5, 212-220	3
680	Implementation of an intervention bundle leads to quality improvement in ulcerative colitis endoscopy reporting. <b>2020</b> , 2, 309-317	0
679	Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase. <b>2020</b> , 13, 1756284820968747	1

678	Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. <b>2020</b> , 39, 3543-3553	3
677	Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. <b>2020</b> , 11, e00174	9
676	Comparison between Diffusion-Weighted Sequences with Selective and Non-Selective Fat Suppression in the Evaluation of Crohn's Disease Activity: Are They Equally Useful?. <b>2020</b> , 10,	
675	Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. <b>2020</b> , 37, 3417-3431	31
674	An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. <b>2020</b> , 39, 176-185	4
673	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <b>2020</b> , 9,	7
672	Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. <b>2020</b> , 52, 704-720	2
671	Updates in diagnosis and management of inflammatory bowel disease. <b>2020</b> , 50, 100785	6
670	Huai hua san alleviates dextran sulphate sodium-induced colitis and modulates colonic microbiota. <b>2020</b> , 259, 112944	5
669	Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study. <b>2020</b> , 15, e0233811	10
668	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <b>2020</b> , 17, 507-516	13
667	Targeting the gut layers in Crohn's disease: mucosal or transmural healing?. <b>2020</b> , 14, 775-787	4
666	Endoscopic scores in inflammatory bowel disease. <b>2020</b> , 189-220	
665	Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy. <b>2020</b> , 14, 1524-1534	5
664	Histologic evaluation of disease activity in inflammatory bowel disease. <b>2020</b> , 221-233	
663	Motivation to pursue anti-TNF treatment in patients with Crohn's disease - the SPACE motivation study. <b>2020</b> , 52, 995-1001	
662	The treatment approach to inflammatory bowel disease in 2020. <b>2020</b> , 36, 247-256	7
661	Treat-to-Target in Pediatric Inflammatory Bowel Disease: What Does the Evidence Say?. <b>2020</b> , 22, 463-472	3

660	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. <b>2020</b> , 69, 658-664		8
659	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 885-894	0.7	6
658	Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults. <b>2020</b> , 10,		21
657	Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?. <b>2020</b> , 9,		2
656	Treatment to target in patients with inflammatory bowel disease. What is the evidence?. <b>2020</b> , 55, 528-536		1
655	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <b>2020</b> , 14, 1503-1511		34
654	Black/African American Patients with Pediatric Crohn's Disease Report Less Anxiety and Fatigue than White Patients. <b>2020</b> , 225, 146-151		0
653	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. <b>2020</b> , 14, 819-828		1
652	A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. <b>2020</b> , 51, 1342-1352		4
651	Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. <b>2020</b> , 52, 292-302		6
650	Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. <b>2020</b> , 52, 284-291		19
649	MicroRNA-320a Monitors Intestinal Disease Activity in Patients With Inflammatory Bowel Disease. <b>2020</b> , 11, e00134		6
648	Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. <b>2020</b> , 20, 100271		13
647	Challenges in the Management of Inflammatory Bowel Disease. <b>2020</b> , 1-16		1
646	Emerging therapies for the treatment of ulcerative colitis. <b>2020</b> , 1-9		5
645	Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. <b>2020</b> , 11, e00138		9
644	A further "stri(v)de" in IBD management. <b>2020</b> , 52, 721-722		
643	Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases. <b>2020</b> , 77, 105-110		2

642	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <b>2020</b> , 9,	16
641	Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. <b>2020</b> , 51, 852-860	13
640	Assessment of Endoscopic Healing by Using Advanced Technologies Reflects Histological Healing in Ulcerative Colitis. <b>2020</b> , 14, 1282-1289	10
639	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <b>2020</b> , 159, 139-147	54
638	Crohn's disease. <b>2020</b> , 6, 22	131
637	1,25(OH) D alleviates DSS-induced ulcerative colitis via inhibiting NLRP3 inflammasome activation. <b>2020</b> , 108, 283-295	13
636	Association of Faecal Calprotectin Level and Combined Endoscopic and Radiological Healing in Patients With Crohn's Disease Receiving Anti-tumour Necrosis Factor Therapy. <b>2020</b> , 14, 1231-1240	6
635	Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission. <b>2020</b> , 11, e00135	5
634	Objective evaluation for treat to target in Crohn's disease. <b>2020</b> , 55, 579-587	8
633	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. <b>2020</b> , 52, 401-402	0
632	Comparison of F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. <b>2020</b> , 93, 20200167	3
631	Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. <b>2020</b> , 13, 211-220	1
630	Histological Healing in Ulcerative Colitis: Near Enough Is Not Good Enough. <b>2020</b> , 14, 1341-1342	2
629	Flare-IBD: development and validation of a questionnaire based on patients' messages on an internet forum for early detection of flare in inflammatory bowel disease: study protocol. <b>2020</b> , 10, e037211	1
628	Optimal strategies to prevent recrudescence Crohn's disease after resection. <b>2020</b> , 31, 100746	
627	Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. <b>2020</b> , 71, 12-18	2
626	Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. <b>2020</b> , 20, 211	6
625	The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. <b>2020</b> , 55, 824-832	0

624	A qualitative inquiry into patients' perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases. <b>2020</b> , 29, 2403-2414	1
623	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial. <b>2020</b> , 5, 900-907	29
622	Comparison of acceptance of PET/MR enterography and ileocolonoscopy in patients with inflammatory bowel diseases. <b>2020</b> , 64, 11-17	1
621	Histologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right?. <b>2020</b> , 26, 1730-1732	
620	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <b>2020</b> , 26, 1562-1571	12
619	Simple water-based tacrolimus enemas for refractory proctitis. <b>2020</b> , 4, 561-564	1
618	Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease. <b>2020</b> , 20, 35	12
617	Editorial: endoscopic inflammation in ileoanal pouches-does it really matter?. <b>2020</b> , 51, 170-171	0
616	Editorial: histologic normalisation in ulcerative colitis. Authors' reply. <b>2020</b> , 51, 401	0
615	Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. <b>2020</b> , 14, 254-266	85
614	Review article: faecal calprotectin and histologic remission in ulcerative colitis. <b>2020</b> , 51, 689-698	29
613	Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. <b>2020</b> , 44, 609-618	1
612	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <b>2020</b> , 14, 896-903	4
611	Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?. <b>2020</b> , 13, 760-769	19
610	Up-to-date surgery for ulcerative colitis in the era of biologics. <b>2020</b> , 20, 391-398	5
609	Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. <b>2020</b> , 15, e0227635	11
608	Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. <b>2020</b> , 24, 105-126	22
607	Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study. <b>2020</b> , 55, 163-168	5

606	Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn's disease in Japan. <b>2020</b> , 10, 511	10
605	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <b>2020</b> , 18, 2500-2509.e1	8
604	The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. <b>2020</b> , 80, 99-113	32
603	Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. <b>2020</b> , 14, 1364-1377	2
602	Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. <b>2020</b> , 51, 1096-1104	9
601	Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <b>2020</b> , 26, 1579-1587	21
600	Segmental Histological Normalisation Occurs in Ulcerative Colitis but Does Not Improve Clinical Outcomes. <b>2020</b> , 14, 1345-1353	5
599	Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine. <b>2020</b> , 35, 1878-1885	5
598	The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study. <b>2020</b> , 21, 264-271	15
597	Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. <b>2020</b> , 5, 598-606	63
596	Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <b>2020</b> , 14, 1413-1423	6
595	Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. <b>2020</b> , 51, 1039-1046	25
594	Herbal medicine for inflammatory bowel diseases: development of pattern identification algorithms by retrospective analysis of case series data. <b>2020</b> , 36, 101114	4
593	Head-to-head trials in inflammatory bowel disease: past, present and future. <b>2020</b> , 17, 365-376	20
592	Using Artificial Intelligence to Identify Patients With Ulcerative Colitis in Endoscopic and Histologic Remission. <b>2020</b> , 158, 2045-2047	3
591	Mucosal healing in Crohn's disease: new insights. <b>2020</b> , 14, 335-345	8
590	Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study. <b>2020</b> , 20, 110	2
589	Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission. <b>2021</b> , 19, 111-118.e10	12

588	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. <b>2021</b> , 15, 152-161	10
587	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <b>2021</b> , 87, 106-118	7
586	Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission. <b>2021</b> , 19, 1226-1233.e1	5
585	Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission. <b>2021</b> , 12, 30-38	0
584	UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. <b>2021</b> , 12, 22-29	3
583	Faecal Biomarkers in Inflammatory Bowel Diseases: Calprotectin Versus Lipocalin-2-a Comparative Study. <b>2021</b> , 15, 43-54	12
582	Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. <b>2021</b> , 19, 1209-1217.e2	8
581	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <b>2021</b> , 27, 106-122	6
580	Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. <b>2021</b> , 27, 647-654	10
579	Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. <b>2021</b> , 70, 85-91	62
578	Systematic Review: Gastrointestinal Ultrasound Scoring Indices for Inflammatory Bowel Disease. <b>2021</b> , 15, 125-142	11
577	Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. <b>2021</b> , 53, 35-43	9
576	Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <b>2021</b> , 19, 908-921.e6	7
575	Fully automated endoscopic disease activity assessment in ulcerative colitis. <b>2021</b> , 93, 728-736.e1	18
574	The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease. <b>2021</b> , 66, 1390-1391	
573	Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study. <b>2021</b> , 66, 1836-1844	4
572	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <b>2021</b> , 15, 143-151	6
571	No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015. <b>2021</b> , 27, 655-661	2



570	Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn's Disease. <b>2021</b> , 4, 73-77	5
569	Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. <b>2021</b> , 36, 864-872	4
568	Systematic Review: Patient Perceptions of Monitoring Tools in Inflammatory Bowel Disease. <b>2021</b> , 4, e31-e41	3
567	The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. <b>2020</b> ,	75
566	Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. <b>2021</b> , 9, 438-442	4
565	Endoscopic imaging in inflammatory bowel disease: current developments and emerging strategies. <b>2021</b> , 15, 115-126	6
564	Quality of care in adult patients with inflammatory bowel disease transferring between healthcare providers: multicentre audit. <b>2021</b> , 12, 5-10	1
563	Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease. <b>2021</b> , 15, 609-616	11
562	Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. <b>2021</b> , 21, 97-104	1
561	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. <b>2021</b> , 53, 403-408	3
560	Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks. <b>2021</b> , 160, 710-719.e2	22
559	Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. <b>2021</b> , 44, 87-95	0
558	Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. <b>2021</b> , 21, 37-46	3
557	Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches?. <b>2021</b> , 39, 190-203	7
556	Week 6 Calprotectin Best Predicts Likelihood of Long-term Endoscopic Healing in Crohn's Disease: A Post-hoc Analysis of the UNITI/IM-UNITI Trials. <b>2021</b> , 15, 462-470	2
555	Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. <b>2021</b> , 36, 943-950	5
554	Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. <b>2021</b> , 14, 17562848211006672	2
553	The Role of Narrowed Spectrum Technologies and Dye-based Endoscopy in Inflammatory Bowel Disease: New Advances and Opportunities. <b>2021</b> , 23, 42-56	0



552	How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. <b>2021</b> , 8, 640813	7
551	Histologic Activity and Steroid Use History are Risk Factors of Clinical Relapse in Ulcerative Colitis with Endoscopic Remission.	
550	Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil. <b>2021</b> , 27, 208-223	4
549	Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. <b>2021</b> , 1-23	
548	Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. <b>2021</b> , 19, 53-61	5
547	Challenges in the Management of Inflammatory Bowel Disease. <b>2021</b> , 1675-1690	
546	Patient-Reported Outcomes in Inflammatory Bowel Diseases: Another Piece in the Puzzle. <b>2021</b> , 15, 1085-1086	
545	Current noninvasive modalities in Crohn's disease monitoring. <b>2021</b> , 34, 770-780	0
544	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <b>2021</b> , 53, 784-793	3
543	Is the Mixed Use of Magnetic Resonance Enterography and Computed Tomography Enterography Adequate for Routine Periodic Follow-Up of Bowel Inflammation in Patients with Crohn's Disease?. <b>2021</b> ,	1
542	Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. <b>2021</b> , 86, 70-85	
541	Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study. <b>2021</b> , 21, 13	0
540	Crohn Disease. <b>2021</b> , 461-473.e8	
539	Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease. <b>2021</b> , 86, 70-85	
538	Fecal calprotectin as a noninvasive test to predict deep remission in patients with ulcerative colitis. <b>2021</b> , 100, e24058	2
537	Capsule Endoscopy Is Useful for Postoperative Tight Control Management in Patients with Crohn's Disease. <b>2021</b> , 1	4
536	Gastrointestinal Disorders: Inflammatory Bowel Disease and Irritable Bowel Syndrome. <b>2021</b> ,	
535	Sulfated polysaccharides from pacific abalone attenuated DSS-induced acute and chronic ulcerative colitis in mice regulating intestinal micro-ecology and the NF- $\kappa$ B pathway. <b>2021</b> , 12, 11351-11365	5

534	Clinical Outcomes and Response Predictors of Vedolizumab Induction Treatment for Korean Patients With Inflammatory Bowel Diseases Who Failed Anti-TNF Therapy: A KASID Prospective Multicenter Cohort Study. <b>2021</b> , 27, 1931-1941	1
533	New Therapeutics for Ulcerative Colitis. <b>2021</b> , 72, 199-213	7
532	Baitouweng Decoction Ameliorates Ulcerative Colitis in Mice Partially Attributed to Regulating Th17/Treg Balance and Restoring Intestinal Epithelial Barrier. <b>2020</b> , 11, 531117	7
531	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. <b>2021</b> , 61-88	0
530	A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative Colitis. <b>2021</b> , 15, 1284-1290	7
529	Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. <b>2021</b> , 14, 17562848211006669	7
528	Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease. <b>2021</b> , 44, 87-95	
527	Clinical Practice Survey of Repeat Endoscopy in Pediatric Inflammatory Bowel Disease in North America. <b>2021</b> , 73, 61-66	
526	Predicting Therapeutic Response in Pediatric Ulcerative Colitis-A Journey Towards Precision Medicine. <b>2021</b> , 9, 634739	1
525	Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. <b>2021</b> , 15, 938-949	8
524	Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. <b>2021</b> , 72, 870-876	1
523	Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. <b>2021</b> , 10,	4
522	Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. <b>2021</b> , 23, e15946	2
521	Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico. 9, 1496	
520	Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis. <b>2021</b> , 1	1
519	Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis. <b>2021</b> , 3,	0
518	Medical and Endoscopic Management of Crohn Disease. <b>2021</b> , 30, 43-61	
517	Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?. <b>2021</b> , 15, 1087-1088	

516	Scoring Endoscopy in Pediatric Inflammatory Bowel Disease: A Way to Improve Quality. <b>2021</b> , 73, 48-53	
515	Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. <b>2021</b> ,	15
514	Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. <b>2021</b> , 36, 1744-1753	2
513	Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort. <b>2021</b> , 22, 66-72	0
512	Ulcerative colitis: an update. <b>2021</b> , 21, 135-139	4
511	Patient perceptions of current and potential inflammatory bowel disease diagnostic and monitoring tests. <b>2021</b> ,	0
510	Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know. <b>2021</b> , 37, 320-327	1
509	Real-life evaluation of histologic scores for Ulcerative Colitis in remission. <b>2021</b> , 16, e0248224	1
508	Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration. <b>2021</b> , 15, 1091-1096	1
507	Dispositional Mindfulness and Inflammatory Bowel Disease: Mindful Awareness Mediates the Relation Between Severity and Quality of Life, Stress, and Fatigue. <b>2021</b> , 12, 1524-1533	3
506	Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). <b>2021</b> ,	0
505	The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. <b>2021</b> , 87, 3776-3789	0
504	Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. <b>2021</b> , 33, 670-679	4
503	New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. <b>2021</b> , 22, 370-378	
502	C-reactive protein/albumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: A retrospective study. <b>2021</b> , 100, e24925	3
501	Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. <b>2021</b> , 1	2
500	Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. <b>2021</b> , 15, 232-242	2
499	Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI on quality of life and quality of care in patients with inflammatory bowel disease. <b>2021</b> , 56, 530-536	1

498	Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. <b>2021</b> , 27, 866-885	
497	Drug development for ulcerative proctitis: current concepts. <b>2021</b> , 70, 1203-1209	1
496	Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease. <b>2021</b> , 12, e00320	3
495	The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. <b>2021</b> , 30, 1925-1938	1
494	Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation. <b>2021</b> , 14, 667-678	4
493	Dialing Back M for Monoclonal: Successful De-escalation of Dose-Intensified Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. <b>2021</b> , 1	
492	Automated endoscopic assessment in ulcerative colitis: the next frontier. <b>2021</b> , 93, 737-739	2
491	Serum biomarkers confirming stable remission in inflammatory bowel disease. <b>2021</b> , 11, 6690	6
490	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis. <b>2021</b> , 15, 1649-1657	0
489	Validation of the 'Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn's Disease. <b>2021</b> , 15, 1621-1630	4
488	Treat-to-target approach in the management of inflammatory Bowel disease. <b>2021</b> , 44, 312-319	7
487	The Great Debate With IBD Biosimilars. <b>2021</b> , 3,	1
486	Xi Lei San Attenuates Dextran Sulfate Sodium-Induced Colitis in Rats and TNF--Stimulated Colitis in CACO2 Cells: Involvement of the NLRP3 Inflammasome and Autophagy. <b>2021</b> , 2021, 1610251	2
485	An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICA <sup>SSO</sup> in Ulcerative Colitis. <b>2021</b> , 160, 1558-1569.e8	9
484	Radiological targets in inflammatory bowel disease: An evolving paradigm. <b>2021</b> , 36 Suppl 1, 10-11	
483	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <b>2021</b> ,	2
482	Advances in the Comprehensive Management of Postoperative Crohn's Disease. <b>2021</b> ,	5
481	Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. <b>2021</b> ,	2

480 Treat-to-target approach in the management of inflammatory Bowel disease. **2021**, 44, 312-319

479 Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. **2021**, 2

478 Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. **2021**, 1

477 Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn's Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents. **2021**, 2

476 Lactose Intolerance Assessed by Analysis of Genetic Polymorphism, Breath Test and Symptoms in Patients with Inflammatory Bowel Disease. **2021**, 13, 2

475 Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. **2021**, 53, 434-441

474 Integrating a treat to target approach into clinical practice in 2020. **2021**, 36 Suppl 1, 6-7

473 Endoscopic and histologic endpoints as treatment targets: Are we there yet?. **2021**, 36 Suppl 1, 8-9

472 Pathologist, Meet Picasso! Virtual Chromoendoscopy for Detecting Histologic Remission in Ulcerative Colitis. **2021**, 160, 1469-1472 1

471 Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months. **2021**, 21, 161 1

470 Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis. **2021**, 15, 1631-1640 2

469 What are the treatment targets in inflammatory bowel disease (IBD) in 2020?: Session one summary. **2021**, 36 Suppl 1, 4-5 1

468 Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. **2021**, 160, 1452-1460.e21 15

467 STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. **2021**, 160, 1570-1583 191

466 Conservative management of spontaneous intra-abdominal abscess in Crohn's disease: Outcome and prognostic factors. **2021**, 22, 263-270 1

465 A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. *American Journal of Gastroenterology*, **2021**, 116, 1709-1719 0.7 0

464 Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. **2021**, 56, 489-526 40

463 Protective Effect of on Inflammation in a DSS-Induced Colitis Rat Model. **2021**, 10, 2

- 462 Clinical, biomarker and endoscopic outcomes in patients with Crohn's disease treated with Ustekinumab: Multi-centre real world study. **2021**, 3, 151-160
- 461 Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission. **2021**, 27, 1719-1730<sup>1</sup>
- 460 Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. **2021**, 3, 1
- 459 Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. **2021**, 9, 661536 2
- 458 Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. **2021**, 3, 0
- 457 Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. **2021**, 27, 2521-2530 2
- 456 Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia. **2021**, 2
- 455 Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. **2021**, 10, 7
- 454 Diagnostic accuracy of patient-reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis. **2021**, 3, 161-168 1
- 453 Is Paradigm for the Role of Balloon-Assisted Enteroscopy Changing in Crohn's Disease?. **2021**, 15, 325-326
- 452 Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece. **2021**, 1
- 451 Granulocyte and monocyte apheresis as an adjunctive therapy to induce and maintain clinical remission in ulcerative colitis: a systematic review and meta-analysis. **2021**, 11, e042374 1
- 450 Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. **2021**, 15, 401-409 2
- 449 Irritable Bowel Syndrome in Inflammatory Bowel Disease. Synergy in alterations of the gut-brain axis?. **2021**, 0
- 448 Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. **2021**, 45, 165-165 1
- 447 Treating inflammatory bowel diseases in the 21st century: individualized therapy and telemedicine. **2021**, 67, 201-205
- 446 Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. **2021**, 10, 1
- 445 Raman spectroscopy accurately differentiates mucosal healing from non-healing and biochemical changes following biological therapy in inflammatory bowel disease. **2021**, 16, e0252210 0

444	Use of the ulcerative colitis endoscopic index of severity and Mayo endoscopic score for predicting the therapeutic effect of mesalazine in patients with ulcerative colitis. <b>2021</b> , 4, 33-39	0
443	Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. <b>2021</b> , 1	0
442	Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. <b>2021</b> , 17, 871-881	1
441	Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. <b>2021</b> , 27, 3396-3412	1
440	Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting. <b>2021</b> , 56, 906-913	0
439	CXCL8 chemokine in ulcerative colitis. <b>2021</b> , 138, 111427	11
438	Clinical utility of small bowel ultrasound assessment of Crohn's disease in adults: a systematic scoping review. <i>flgastro-2021-101897</i>	0
437	Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease. <b>2021</b> , 54, 652-666	0
436	Exploring the Mechanism of Berberine Intervention in Ulcerative Colitis from the Perspective of Inflammation and Immunity Based on Systemic Pharmacology. <b>2021</b> , 2021, 9970240	3
435	Assessment of the Relationship between Ulcerative Colitis and Forkhead Box P3 Polymorphisms. <b>2021</b> , 32, 287-293	
434	Transmural Response and Transmural Healing Defined by Intestinal Ultrasound - New Potential Therapeutic Targets?. <b>2021</b> ,	0
433	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <b>2021</b> , 160, 2291-2302	10
432	Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. <b>2021</b> ,	1
431	Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis. <b>2021</b> , 9, E1116-E1122	0
430	Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. <b>2021</b> , 19, 2293-2301.e1	0
429	Bewachung und Management von Dysplasien bei chronisch-entzündlichen Darmerkrankungen. <b>2021</b> , 16, 267-277	
428	Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis. <b>2021</b> ,	1
427	Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. <b>2021</b> , 19, 1170-1179.e10	2

426	The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. <b>2021</b> , 31, 020707	1
425	Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique. <b>2021</b> , 37, 1547-1554	0
424	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. <b>2021</b> , 397, 2372-2384	36
423	Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring.	
422	Endoscopic and Histologic Predictors of Outcomes in Pediatric Ulcerative Colitis-. <b>2021</b> , 9, 678132	
421	Gastrointestinal endoscopy in children and adults: How do they differ?. <b>2021</b> , 53, 697-705	1
420	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <b>2021</b> , 53, 1571-1579	0
419	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. <b>2021</b> , 6, 482-497	9
418	Efficacy and safety of hyperbaric oxygen therapy for moderate-to-severe ulcerative colitis: a protocol for a systematic review and meta-analysis. <b>2021</b> , 11, e047543	0
417	Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. <b>2021</b> , 54, 234-248	5
416	Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. <b>2021</b> , 20, 102832	8
415	Classification According to Subjectivity of Inflammatory Bowel Disease Patients Using Q Methodology. <b>2021</b> , 78, 1-2	
414	Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. <b>2021</b> , 161, 47-65	8
413	Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease. <b>2021</b> , 33, 1280-1287	0
412	Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing. <b>2021</b> ,	0
411	Real-life utility and diagnostic accuracy of a home-performed fecal calprotectin test to predict endoscopic activity in patients with inflammatory bowel disease under maintenance treatment with adalimumab. <b>2021</b> ,	1
410	[Position paper on endoscopic reporting in IBD]. <b>2021</b> , 59, 1091-1109	1
409	Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis. <b>2021</b> ,	4



408	Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study. <b>2021</b> , 1	1
407	Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow. <b>2021</b> , 2, 65-74	
406	Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. <b>2021</b> , 27, 1552-1563	1
405	Apex Score: Predicting Flares in Small-Bowel Crohn's Disease After Mucosal Healing. <b>2021</b> , 1	0
404	Is the APEX Score the Pinnacle of Predictive Scoring Systems of Disease Flare in Crohn's Patients with Documented Mucosal Healing?. <b>2021</b> , 1	
403	Visceral Adipose Tissue Volumetrics Inform Odds of Treatment Response and Risk of Subsequent Surgery in IBD Patients Starting Antitumor Necrosis Factor Therapy. <b>2021</b> ,	2
402	Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. <b>2021</b> , 53, 803-808	10
401	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. <b>2021</b> , 54, 944-951	2
400	Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. <b>2021</b> , 16, e0254548	0
399	Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. <b>2021</b> , 18,	2
398	Magnetic resonance enterography in Crohn's disease patients: current state of the art and future perspectives. <b>2021</b> , 18, 657-667	1
397	Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center.	
396	Viral infections in inflammatory bowel disease: Tips and tricks for correct management. <b>2021</b> , 27, 4276-4297	2
395	Subjective Needs and Thoughts for the Treatment of Patients with Inflammatory Bowel Disease: Applying Q Methodology. <b>2021</b> , 78, 37-47	1
394	Approach to medical therapy in perianal Crohn's disease. <b>2021</b> , 27, 3693-3704	0
393	Twenty-five years of biologicals in IBD: What's all the hype about?. <b>2021</b> , 290, 806-825	5
392	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques. <b>2021</b> ,	1
391	Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. <b>2021</b> , 6, 659-667	6

- 390 Molecular mechanism of Huaihuasan in treatment of ulcerative colitis based on network pharmacology and molecular docking. **2021**, 1, 100081 3
- 389 Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF- $\alpha$  Patients With Moderate-to-Severe Ulcerative Colitis in China. **2021**, 9, 704889 2
- 388 Clinical communication in inflammatory bowel disease: a systematic review of the study of clinician-patient dialogue to inform research and practice. **2021**, 11, e051053
- 387 Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis. **2021**, 20, 43-50
- 386 Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNF $\alpha$  inflammatory bowel disease. **2021**, 21, 312 0
- 385 Designing Consumer Health Information Technology to Support Biform and Articulation Work: A Qualitative Study of Diet and Nutrition Management as Patient Work. **2021**, 8, e27452 0
- 384 Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?. **2022**, 7, 7-12 1
- 383 E-Health and remote management of patients with inflammatory bowel disease: lessons from Denmark in a time of need. **2021**, 51, 1207-1211 2
- 382 Artificial intelligence assisted assessment of endoscopic disease activity in inflammatory bowel disease. **2021**, 2, 95-102
- 381 Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. **2021**, 5, 1056-1062 0
- 380 Predictivity of early and late assessment for post-surgical recurrence of Crohn's disease: Data from a single-center retrospective series. **2021**, 53, 987-995 4
- 379 Efficacy of tofacitinib as a «rescue therapy» in patients with severe ulcerative colitis. **2021**, 20, 43-50 1
- 378 Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. **2021**, 0
- 377 Precision medicine and inflammatory bowel diseases: concept, strategies, future. **2021**, 1, 121-129 1
- 376 Stopping Anti-TNF in CD Remitters: Cons.. **2022**, 7, 59-63
- 375 Eosinophilic esophagitis: When pathologists make the difference. **2021**, 98, 1-1
- 374 Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD. **2021**, 175, 113828 4
- 373 State-of-the-art surgery for ulcerative colitis. **2021**, 406, 1751-1761 0

372	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 2014-2025	0.7	13
371	Assessing adherence to objective disease monitoring and outcomes with adalimumab in a real-world IBD cohort. <b>2021</b> , 53, 980-986		0
370	Preventive and Prebiotic Effect of Galacto-Oligosaccharide against Dextran Sodium Sulfate-Induced Colitis and Gut Microbiota Dysbiosis in Mice. <b>2021</b> , 69, 9597-9607		2
369	Is histological remission of ulcerative colitis achievable?. <b>2021</b> , 93, 975-981		1
368	Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. <b>2021</b> ,		3
367	Predictors of health-related quality of life in patients with Crohn's disease receiving biological therapy. <b>2021</b> , 56, 1434-1441		
366	Development of a machine-learning model to assess terminal ileum Endoscopic healing in pediatric Crohn's disease from Magnetic Resonance Enterography data.		
365	Role of hospitalization for inflammatory bowel disease in the post-biologic era. <b>2021</b> , 9, 7632-7642		
364	H19 Overexpression Improved Efficacy of Mesenchymal Stem Cells in Ulcerative Colitis by Modulating the miR-141/ICAM-1 and miR-139/CXCR4 Axes. <b>2021</b> , 2021, 7107705		0
363	Quantification of Digestive Disease Damage in Crohn's Disease, Are We There Yet With the Lhann Index?. <b>2021</b> , 161, 800-802		0
362	The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <b>2021</b> , 50, 689-711		1
361	Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis. <b>2021</b> , 16, e0257599		
360	Factors associated with quality of life in Italian children and adolescents with IBD. <b>2021</b> , 11, 18076		0
359	Patient access to biological medications for ulcerative colitis. <b>2021</b> , 19, 32-39		1
358	Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals. <b>2021</b> , 10,		2
357	Increased Use of Anti-Tumor Necrosis Factor Following the Implementation of the ECCO-ESPGHAN Guidelines and its Impact on the Outcome of Pediatric Crohn's Disease: A Retrospective Single-Center Study.. <b>2022</b> , 74, 79-84		1
356	Web-based and machine learning approaches for identification of patient-reported outcomes in inflammatory bowel disease. <b>2021</b> ,		
355	Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. <b>2021</b> , 8, 737256		3

- 354 Outcomes Related to Mucosal Healing in Patients With Crohn's Disease. **2021**, 19, 2214
- 353 Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease. **2021**, 43, 645-651 2
- 352 Motion-based camera localization system in colonoscopy videos. **2021**, 73, 102180 3
- 351 Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. **2021**, 27, 6231-6247 3
- 350 Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). **2021**, 161, 1156-1167.e3 2
- 349 Anti-tumour necrosis factor antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. **2021**, 100, 108081
- 348 Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNF-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial. **2021**, 102, 742-752 1
- 347 The role of small-bowel endoscopy in inflammatory bowel disease: an updated review on the state-of-the-art in 2021. **2021**, 34, 599-611 2
- 346 Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. **2021**, 14, 1756284821994741 2
- 345 Evaluation of ulcerative colitis activity using transabdominal ultrasound shear wave elastography.. **2022**, 12, 618-626 0
- 344 Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?. **2021**, 14, 17562848211005692
- 343 Is histological healing a feasible endpoint in ulcerative colitis?. **2021**, 15, 665-674 0
- 342 Parent Perspectives of Diagnostic and Monitoring Tests Undertaken by Their Child with Inflammatory Bowel Disease. **2021**, 24, 19-29 1
- 341 The Impact of a Real-Life Inflammatory Bowel Disease Education Course for Brazilian Physicians from the Perspective of Its Participants. **2021**, 11, 151-160
- 340 Comparison of transmural healing and mucosal healing as predictors of positive long-term outcomes in Crohn's disease. **2021**, 14, 17562848211016259 2
- 339 Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. **2020**, 7, 613475 3
- 338 Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. **2021**, 14, 1756284820980860 9
- 337 Sleep Disturbance in Inflammatory Bowel Disease Is Associated with Disease Activity and Adverse Outcome. **2021**, 39, 496-501 1

336	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. <b>2021</b> , 478, 581-594	8
335	[Crohn's disease and autologous hemapoietic cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. <b>2020</b> , 107, S140-S150 <sup>o</sup>	
334	GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. <b>2020</b> , 43 Suppl 1, 1-57	3
333	Established Management Paradigms in IBD: Treatment Targets and Therapeutic Tools. <b>2016</b> , 3, 8-16	6
332	Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. <b>2020</b> , 55, 656-663	4
331	End of Induction Patient-reported Outcomes Predict Clinical Remission but Not Endoscopic Remission in Crohn's Disease. <b>2021</b> , 15, 1114-1119	2
330	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. <b>2021</b> , 15, 766-773	1
329	Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. <b>2021</b> , 27, 1277-1284	1
328	Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom. <b>2021</b> , 27, 1593-1601	1
327	Use of Small Bowel Ultrasound to Predict Response to Infliximab Induction in Pediatric Crohn's Disease. <b>2021</b> , 55, 429-432	2
326	Systematic review and meta-analysis of dermatological reactions in patients with inflammatory bowel disease treated with anti-tumour necrosis factor therapy. <b>2021</b> , 33, 346-357	5
325	Mucosal and Histologic Healing in Children With Inflammatory Bowel Disease Treated With Antitumor Necrosis Factor-Alpha. <b>2021</b> , 72, 728-735	2
324	Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. <b>2018</b> , 47, 454-465	87
323	Biologic therapies for Crohn's disease: optimising the old and maximising the new. <b>2019</b> , 8,	10
322	Precision medicine in inflammatory bowel disease: concept, progress and challenges. <b>2020</b> , 9,	29
321	Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. <b>2017</b> , 12, e0179266	23
320	Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 134-141	0.7 5
319	Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 125-133	0.7 2

318	Draft interdisciplinary guidelines for diagnosis, methods for estimation of the degree of activity, for evaluation of therapeutic efficacy, and for use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease). <b>2018</b> , 12, 4-18	11
317	Early prescription of biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An expert opinion. <b>2020</b> , 14, 7-18	3
316	A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. <b>2020</b> , 7, 49-55	5
315	Normalization of long-term quality of life in Crohn's disease patients receiving ustekinumab. <b>2021</b> , 113, 313-317	4
314	Budesonide in the treatment of ulcerative colitis: real world clinical practice. <b>2019</b> , 47, 505-510	1
313	Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?. <b>2019</b> , 25, 64-68	3
312	Implication of Medical Treatment for Surgical Strategies in IBD. <b>2019</b> , 20, 1363-1368	0
311	'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. <b>2021</b> , 22, 117-125	2
310	Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review. <b>2019</b> , 21, e14630	23
309	Medication Use and Drug Expenditure in Inflammatory Bowel Disease: based on Korean National Health Insurance Claims Data (2010-2014). <b>2019</b> , 29, 79-88	6
308	Efficacy of Rose Oil Soft Capsules on Clinical Outcomes in Ulcerative Colitis: A Pilot Randomized, Double-Blinded, Placebo-Controlled Clinical Trial. <b>2019</b> , 8, e1307	2
307	CROHN'S DISEASE. CLINICAL RECOMMENDATIONS (PRELIMINARY VERSION). <b>2020</b> , 19, 8-38	34
306	Simple pain measures reveal psycho-social pathology in patients with Crohn's disease. <b>2017</b> , 23, 1076-1089	8
305	Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. <b>2018</b> , 24, 3567-3582	27
304	Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. <b>2018</b> , 24, 4014-4020	30
303	Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. <b>2018</b> , 24, 4384-4392	16
302	Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease. <b>2019</b> , 25, 1764-1774	5
301	Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease. <b>2019</b> , 25, 2354-2364	8

300	Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. <b>2019</b> , 25, 4158-4171	13
299	Small bowel capsule endoscopy and treat-to-target in Crohn's disease: A systematic review. <b>2019</b> , 25, 4534-4554	18
298	Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial. <b>2019</b> , 25, 6158-6171	7
297	Disease monitoring strategies in inflammatory bowel diseases: What do we mean by "tight control"? <b>2019</b> , 25, 6172-6189	12
296	Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results. <b>2020</b> , 26, 2852-2863	2
295	Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift?. <b>2020</b> , 26, 3712-3719	3
294	Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. <b>2020</b> , 26, 4428-4441	6
293	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. <b>2020</b> , 26, 6710-6769	4
292	Proteomic insights on the metabolism in inflammatory bowel disease. <b>2020</b> , 26, 696-705	3
291	Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes. <b>2020</b> , 26, 759-769	2
290	The missing "C": Crohn's, colitis and coping. <b>2019</b> , 25, 143-144	3
289	Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease. <b>2019</b> , 25, 159-166	16
288	Depressive Symptoms and Quality of Life in the Patients of Inflammatory Bowel Disease. <b>2017</b> , 11, 449-450	3
287	Improving the quality of care for inflammatory bowel disease. <b>2019</b> , 17, 45-53	10
286	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. <b>2019</b> , 17, 504-515	9
285	Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study. <b>2021</b> , 19, 408-418	3
284	Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. <b>2020</b> , 18, 347-354	5
283	Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. <b>2020</b> , 9,	6

- 282 Predictive values of stool-based tests for mucosal healing among Taiwanese patients with ulcerative colitis: a retrospective cohort analysis. **2020**, 8, e9537 7
- 281 Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. **2021**, 0
- 280 Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. **2021**, 13, 1
- 279 Point-of-care intestinal ultrasound in IBD patients: disease management and diagnostic yield in a real-world cohort and proposal of a point-of-care algorithm. **2021**, 0
- 278 Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice. **2021**, 144-151
- 277 Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study. **2021**, 21, 380 3
- 276 Radiology plus ileocolonoscopy versus radiology alone in Crohn's disease: prognosis prediction and mutual agreement. **2021**, 0
- 275 Reply. **2021**, 19, 2452-2454
- 274 Endoscopy and Inflammatory Bowel Disease. **2017**, 247-271 1
- 273 Esophagogastroduodenoscopy and Ileocolonoscopy. **2018**, 39-46
- 272 Endoscopic Score in CD and UC. **2018**, 47-54
- 271 The Role of Biopsies in the Treatment of Colitis: Scoring of Disease Activity. **2018**, 243-250
- 270 Conventional and biological therapy for inflammatory bowel disease. **2018**, 64, 642-653 1
- 269 DIAMOND study: an additional evidence of the interest of being proactive in IBD. **2018**, 6, 279
- 268 A draft of the interdisciplinary guidelines for diagnosis, methods for assessment of the degree of inflammatory activity, therapeutic efficacy, and for the use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Crohn's disease). **2018**, 46, 426-444 2
- 267 Toward Personalized Therapy in Inflammatory Bowel Disease. **2019**, 381-389
- 266 Medical Management 1: General. **2019**, 75-79
- 265 Genetic Risk Prediction in IBD. **2019**, 141-156



- 264 Clinical Trial Design to Facilitate Biomarker Discovery. **2019**, 45-53
- 263 The main determinants of disability in IBD and its relationship to optimism. **2019**, 111, 579-585 3
- 262 Disease Modification in Crohn's Disease. **2019**, 23-29
- 261 Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review (Preprint).
- 260 Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores?. **2019**, 11, 424-426
- 259 Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study (Preprint).
- 258 Ultrasensitive Molecular Imaging of Mucosal Inflammation Using Leucocyte-Mimicking Particles Targeted to MAdCAM-1.
- 257 Current Approaches to Planning and Conducting Clinical Trials of Medicinal Products for the Treatment of Crohn's Disease. **2020**, 10, 111-120
- 256 Strengthened monitoring and optimized management of Crohn's disease patients. **2020**, 28, 660-668
- 255 Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. **2021**, 33, 54-61 2
- 254 Clinical Application of Artificial Intelligence to Evaluate Disease Activity in Patients with Ulcerative Colitis. **2020**, 76, 97-98 1
- 253 Le recours à la chirurgie est-il parfois trop tardif dans le cadre des MICI ?. **2020**, 14, 159-166
- 252 Research in inflammatory bowel disease in Brazil: a step forward towards patient care. **2020**, 57, 225-226 1
- 251 Burden of Inflammatory Bowel Disease on Patient Mood, Fatigue, Work and Health-Related Quality of Life in Thailand: A Case-Control Study.
- 250 A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease. **2021**, 10, 2
- 249 Measuring Histologic Activity in Inflammatory Bowel Disease: Why and How. **2022**, 29, 37-47 0
- 248 Precision Medicine in Pediatric Inflammatory Bowel Disease. **2021**, 68, 1171-1190 0
- 247 Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. **2019**, 65, 280-290 1

- 246 Editorial: Gastrointestinal 2020: Novel inflammatory bowel disease treatments and therapeutic drug monitoring. **2020**, 55, iii-vi
- 245 Colitis ulcerativa para no gastroenterólogos. **2020**, 34, 188-197
- 244 Patient knowledge of fecal calprotectin in inflammatory bowel disease (IBD): An observational study in Mexico. 9, 1496
- 243 Early administration of genetically engineered biological agents for immune-mediated inflammatory diseases: opportunities and prospects. An experts' opinion. **2020**, 48, 422-436 5
- 242 INFLAMMATORY BOWEL DISEASE CARE IN BRAZIL: HOW IT IS PERFORMED, OBSTACLES AND DEMANDS FROM THE PHYSICIANS' PERSPECTIVE. **2020**, 57, 416-427 3
- 241 Development and Testing of a New Simplified Endoscopic Mucosal Assessment for Crohn's Disease: The SEMA-CD. **2021**, 27, 1585-1592 0
- 240 Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID. **2021**, 15, 1000-1008 1
- 239 Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. **2020**, 1
- 238 Biomarkers for Early Detection of Colitis-associated Colorectal Cancer - Current Concepts, Future Trends. **2021**, 22, 137-145 2
- 237 Grundprinzipien der CED-Behandlung. **2020**, 199-205 0
- 236 Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease. **2020**, 13, 1756284820979765 1
- 235 Klassifikationen, Indizes, Aktivitätsbeurteilung. **2020**, 117-136
- 234 Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. **2020**, 13, 1756284820976923 1
- 233 Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. **2022**, 485-507
- 232 Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. **2021**, 11, e054154 1
- 231 Mucosal Healing in Crohn's Disease: Bull's Eye or Bust? "The Pro Position".. **2022**, 7, 36-41
- 230 Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. **2021**, 7
- 229 Guía de práctica clínica para el tratamiento de la enfermedad de Crohn en población adulta. **2020**, 35, 63-200

228	Update on Magnetic Resonance Imaging and Ultrasound Evaluation of Crohn's Disease. <b>2016</b> , 12, 226-36	7
227	A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. <b>2018</b> , 14, 1-12	3
226	Implementing Dietary Modifications and Assessing Nutritional Adequacy of Diets for Inflammatory Bowel Disease. <b>2019</b> , 15, 133-144	5
225	Targeting Mucosal Healing in Crohn's Disease. <b>2019</b> , 15, 529-538	4
224	Development of a Software for Treat-To-Target Strategy Implementation and Increasing Quality of Life in Patients with Inflammatory Bowel Disease. <b>2020</b> , 46, 103-110	1
223	The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice. <b>2021</b> , 17, 3-13	0
222	Disease Activity Assessment: What Should We Do in Clinical Practice?. <b>2021</b> , 17, 10-12	
221	Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.. <b>2021</b> , 16, 257-296	2
220	The Natural History of Inflammatory Bowel Disease. <b>2021</b> , 19, 597	0
219	Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis. <b>2021</b> , 15, 793-794	
218	Crohn's Disease. <b>2022</b> , 379-391	
217	Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. <b>2021</b> ,	1
216	Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study.. <b>2021</b> , 14,	0
215	Gastrointestinale Erkrankungen: Forschungsschwerpunkte der Pharmafirmen. <b>2021</b> , 71, S5-S6	
214	Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?. <b>2021</b> , 10,	1
213	Medical Therapy for Crohn's Disease. <b>2022</b> , 781-798	
212	Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?. <b>2021</b> , 11,	0
211	Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease. <b>2021</b> ,	1

210	Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. <b>2021</b> ,	3
209	A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence. <b>2021</b> , 1-8	0
208	Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey.. <b>2021</b> , 33, e837-e842	
207	Evolving short- and long-term goals of management of IBD: getting it right, making it last.. <b>2021</b> ,	1
206	Longitudinal Bowel Behavior Assessed by Bowel Ultrasound to Predict Early Response to Anti-TNF Therapy in Patients with Crohn's Disease: A Pilot Study.. <b>2022</b> ,	0
205	The value of multi-modes of ultrasound in evaluating segmental mucosal healing in patients with Crohn's disease.. <b>2022</b> ,	
204	Cholinergic immunomodulation in inflammatory bowel diseases.. <b>2022</b> , 19, 100401	3
203	HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE IS ASSOCIATED WITH REDUCTION IN SCHOOL AND WORK PRODUCTIVITY RATHER THAN PHYSICAL IMPAIRMENT: A MULTIDISCIPLINARY STUDY.. <b>2021</b> , 58, 541-547	0
202	Ultrasound use to assess Crohn's disease in the UK: a survey of British Society of Gastroenterology Inflammatory Bowel Disease Group members. flgastro-2021-102065	0
201	Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis.. <b>2022</b> , 1-12	0
200	How should pain, fatigue and emotional wellness be incorporated into treatment goals for optimal management of IBD?. <b>2021</b> ,	1
199	Point-of-care testing and home testing: pragmatic considerations for widespread incorporation: stool tests, serum tests, intestinal ultrasound.. <b>2021</b> ,	0
198	Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises.. <b>2022</b> , 3, 100089	0
197	OUP accepted manuscript.	1
196	Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis.	
195	Medical treatment of intestinal Crohn's disease. <b>2022</b> , 100862	
194	Medical treatment of ulcerative colitis. <b>2022</b> , 33, 100863	0
193	İnflamatuvar Barsak Hastalarında Vedolizumab Deneyimi: Tek Merkez Verileri.	

- 192 Using MR Enterography and CT Enterography for Routine Crohn's Surveillance: How We Do It Now, and How We Hope to Do it in the Future.. **2022**, 23, 1-5 1
- 191 Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.. **2022**, 1 0
- 190 Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission.. **2022**, 12, 507 0
- 189 Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough.. **2022**, 35, 32-43 1
- 188 Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy.. **2022**, 13, 0
- 187 Irritable bowel syndrome in inflammatory bowel disease. Synergy in alterations of the gut-brain axis?. **2022**, 45, 66-76
- 186 Histologic Evaluation Using the Robarts Histopathology Index in Patients With Ulcerative Colitis in Deep Remission and the Association of Histologic Remission With Risk of Relapse.. **2022**,
- 185 Case 3-2022: A 14-Year-Old Boy with Fever, Joint Pain, and Abdominal Cramping.. **2022**, 386, 375-383
- 184 Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.. **2022**, 3
- 183 Therapeutic effect of *Patrinia villosa* on TNBS-induced ulcerative colitis via metabolism, vitamin D receptor and NF- $\kappa$ B signaling pathways.. **2022**, 288, 114989 1
- 182 Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse. **2022**, 2, 33-38 1
- 181 Évaluation des algorithmes de prise en charge de la RCH dans la vraie vie. **2016**, N° 1, 31-38
- 180 Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. **2022**, 0
- 179 Indication of Small Bowel Evaluation in Crohn's Disease. **2022**, 197-199
- 178 Small bowel Crohn's disease: optimal modality for diagnosis and monitoring.. **2022**,
- 177 Efficacy of sigmoidoscopy for evaluating disease activity in patients with ulcerative colitis.. **2022**, 22, 83
- 176 Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients.. **2022**, 11, 0
- 175 Use of mHealth by Patients with Immune-Mediated Inflammatory Diseases: Cross-Sectional Survey (Preprint).

- 174 Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images.. **2022**, 12, 2748 6
- 173 Predictors of each quality of life dimension in Crohn's disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics.. **2022**, 1-8
- 172 Histological Scores in Patients with Inflammatory Bowel Diseases: The State of the Art.. **2022**, 11, 0
- 171 Ulcerative colitis: clinical manifestations and management. **2022**, 1248-1293
- 170 Crohn's disease: clinical manifestations and management. **2022**, 1294-1323
- 169 Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.. **2022**, 22, 92 0
- 168 A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation.. **2022**, 57, 246 0
- 167 Clinical Outcome Assessments in Pediatric Patients With Ulcerative Colitis and Crohn's Disease Receiving Biologics: A Retrospective Cohort Study.
- 166 Low Dose Azathioprine with Allopurinol in IBD: Early Days to Call It a Recipe for Success.. **2022**, 1
- 165 Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease.. **2022**, 1
- 164 Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study.. **2022**, 1
- 163 Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease.. **2022**,
- 162 Aktualisierte S3-Leitlinie Diagnostik und Therapie des Morbus Crohn der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) [August 2021] AWMF-Registernummer: 021-004. **2022**, 60, 332-418 5
- 161 Genetically engineered pH-responsive silk sericin nanospheres with efficient therapeutic effect on ulcerative colitis.. **2022**, 1
- 160 De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation.. **2021**, 34,
- 159 Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials.. **2022**, 0
- 158 Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults.. **2022**, 6, 31 0
- 157 Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1.. **2022**,

156	Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021). <b>2021</b> , 49, 485-495		
155	Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.. <b>2021</b> , 11,		1
154	Low adherence to treatment is a weak link in the problems of ulcerative colitis. <b>2021</b> , 93, 1419-1427		0
153	Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis.. <b>2021</b> ,		1
152	A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.. <b>2021</b> , 36, 85		
151	The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. <b>2021</b> , 21, 456		2
150	Specificity of clinical decision support tools for vedolizumab and ustekinumab in biologically naïve patients with Crohn's disease.. <b>2021</b> , 1-3		
149	Histological remission of ulcerative colitis with combined anti-cytokine and cell therapy. <b>2021</b> , 93, 1435-1442		
148	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.. <b>2021</b> , 1-8		2
147	A narrative systematic review and categorisation of outcomes in Inflammatory Bowel Disease to inform a Core Outcome Set for real-world evidence.. <b>2022</b> ,		0
146	Reproducibility of the electronic chromoendoscopy PICaSSO score (Paddington International Virtual ChromoendoScopy ScOre) in Ulcerative Colitis using multiple endoscopic platforms: A prospective multicenter international study.. <b>2022</b> ,		1
145	HIGH PREVALENCE OF NON-ADHERENCE TO ULCERATIVE COLITIS THERAPY IN REMISSION: KNOWING THE PROBLEM TO PREVENT LOSS.. <b>2022</b> , 59, 40-46		
144	Upregulated NORAD is implicated in apoptosis, inflammation, and oxidative stress in ulcerative colitis through the nuclear factor- $\kappa$ B signaling.. <b>2022</b> , 34,		
143	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel.. <i>American Journal of Gastroenterology</i> , <b>2022</b> ,	0.7	0
142	Adalimumab in Pediatric Inflammatory Bowel Disease.. <b>2022</b> , 10, 852580		1
141	Histological Indices and Risk of Recurrence in Crohn's Disease: A Retrospective Study of a Cohort of Patients in Endoscopic Remission.. <b>2022</b> ,		0
140	Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?. <b>2022</b> ,		2
139	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis.. <b>2022</b> , 11,		0

138 DataSheet\_1.xlsx. **2019**,

137 DataSheet\_2.xlsx. **2019**,

136 DataSheet\_3.xlsx. **2019**,

135 DataSheet\_4.xlsx. **2019**,

134 DataSheet\_5.xlsx. **2019**,

133 Presentation\_1.pdf. **2019**,

132 Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors.. *American Journal of Gastroenterology*, **2022**, 0.7 1

131 Mucosal Healing in Crohn's Disease and Ulcerative Colitis.. **2020**, 16, 206-208

130 Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis.. **2022**, 15, 17562848221092594 1

129 Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. **2022**, 45, 165-176

128 Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. **2022**, 10, 759 0

127 A new Digital Therapeutic Intervention for Patients with Inflammatory Bowel Disease: Program Evaluation (Preprint).

126 Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.. **2022**, 1

125 Capsule Endoscopy versus Magnetic Resonance Enterography for Evaluation of Pediatric Small Bowel Crohn's Disease: Prospective Study. **2022**, 11, 2760 0

124 A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing.. **2022**, 0

123 Ultrasonographic scores for ileal Crohn's disease assessment: Better, worse or the same as contrast-enhanced ultrasound?. **2022**, 22, 252 1

122 Role of functional oligosaccharides as prebiotics on ulcerative colitis. 0

121 The SES-CD Could Be a Predictor of Short- and Long-Term Mucosal Healing After Exclusive Enteral Nutrition in Pediatric Crohn's Disease Patients. **2022**, 10,



- 120 The Impact of Intestinal Ultrasound on the Management of Inflammatory Bowel Disease: From Established Facts Toward New Horizons. **2022**, 9,
- 119 Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, economic and quality-of-life outcomes. 1-40
- 118 Original article: Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn's disease.
- 117 Multi-omics empowered deep phenotyping of ulcerative colitis.
- 116 El índice proteína C reactiva/albumina como marcador para detectar colitis aguda ulcerosa grave en pacientes egipcios. **2022**,
- 115 Tumour necrosis factor-alpha antagonists for treatment of paediatric Crohn's disease. **2022**, 2022,
- 114 Biomechanical Properties of Strictures in Crohn's Disease: Can Dynamic Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography Predict Stiffness?. **2022**, 12, 1370
- 113 Discontinuation of Infliximab Therapy in Patients with Crohn's Disease. o
- 112 Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
- 111 LONG-TERM OUTCOMES AND PREDICTORS OF DISABLING DISEASE IN A POPULATION-BASED COHORT OF PATIENTS WITH INCIDENT CROHN'S DISEASE DIAGNOSED BETWEEN 1994 AND 1997. **2022**, 101974 o
- 110 A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease.
- 109 Managing IBD in patients with previous cancers. **2022**, 13, e44-e50 1
- 108 Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis. 9,
- 107 Carbocysteine as a Modulator of Nrf2/HO-1 and NF- $\kappa$ B Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis. 13, o
- 106 Mucosal p-STAT1/3 correlates with histologic disease activity in Crohn's disease and is responsive to filgotinib.
- 105 LIAISON - Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study.
- 104 Intestinal Ultrasonography as a Tool for Monitoring Disease Activity in Patients with Ulcerative Colitis. **2022**, 2022, 1-6 o
- 103 Treat to transmural healing: how to incorporate intestinal ultrasound into the treatment of inflammatory bowel disease.

- 102 Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. 1-9 1
- 101 Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease. 0
- 100 C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. **2022**,
- 99 Heterogeneity in Efficacy and Safety Endpoints for Pediatric Clinical Trials in Inflammatory Bowel Disease: A Need for Harmonization. **2022**,
- 98 Information and communication technologies in Patients with Immune-Mediated Inflammatory Diseases: Cross-Sectional Survey (Preprint).
- 97 Transmural healing evaluated by magnetic resonance enterography in paediatric patients with Crohn's disease receiving maintenance treatment with biologics.
- 96 Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn's Disease.
- 95 Safety and tolerability of spesolimab in patients with ulcerative colitis. 1-11 0
- 94 Corticosteroid-sparing Effects of Filgotinib in Moderate to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study. 1
- 93 *Rubia cordifolia* L. ameliorates DSS-induced ulcerative colitis in mice through dual inhibition of NLRP3 inflammasome and IL-6/JAK2/STAT3 pathways. **2022**, e10314 0
- 92 Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn's disease. 0
- 91 Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019. 0
- 90 (Re)Appraising Remission in Ulcerative Colitis.
- 89 Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review. 0
- 88 Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. **2022**, 0
- 87 Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms. **2022**, 96-106
- 86 Endocytoscopy for assessing histologic inflammation in ulcerative colitis: development and prospective validation of the ELECT score (ErLangen Endocytoscopy in ColiTis). **2022**, 0
- 85 Prognostic Role of Post-Induction Fecal Calprotectin Levels in Patients with Inflammatory Bowel Disease Treated with Biological Therapies. **2022**, 10, 2305 0

84	Incidence, prevalence, disease course and treatment strategy of Crohn's disease patients from the Veszprem cohort, Western Hungary in a population-based inception cohort study between 2007 and 2018.	1
83	Exploring the concept of deep remission in Crohn's disease: correlation between transmural healing and biomarkers. <b>2022</b> , 15, 175628482211106	0
82	Transabdominal Ultrasound and Magnetic Resonance Enterography in Inflammatory Bowel Disease: Results of an Observational Retrospective Single-Center Study. <b>2022</b> , 08, E22-E28	1
81	Treatment of colitis by oral negatively charged nanostructured curcumin in rats. <b>2022</b> , 37,	0
80	Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn's Disease. <b>2022</b> , 25, 396	0
79	Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease.	0
78	A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application. Volume 18, 913-927	1
77	Elucidating the Anti-Oxidant and Anti-Inflammatory Potentials of Triticum aestivum Against Ulcerative Colitis: an In Vivo and In Silico Study. <b>2022</b> , 100350	0
76	Continuous clinical remission with biologics in ulcerative colitis: the AURORA comparison study. Publish Ahead of Print,	1
75	Biopsy and blood-based molecular biomarker of inflammation in IBD. gutjnl-2021-326451	0
74	Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn's Disease: A Post Hoc Analysis.	0
73	Pilot study of an elimination diet in adults with mild to moderate Crohn's disease. Publish Ahead of Print,	0
72	Holistic healthcare in inflammatory bowel disease: time for patient-centric approaches?. gutjnl-2022-328221	0
71	Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for?. 28, 5300-5312	0
70	Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis. <b>2022</b> , 90-97	0
69	Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus.	0
68	Key research questions for implementation of artificial intelligence in capsule endoscopy. <b>2022</b> , 15, 175628482211326	0
67	Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in IBD: the prospective ERICA trial. <b>2022</b> ,	0

- 66 Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultation. 0
- 65 Challenges and Strategies to Optimising the Quality of Small Bowel Magnetic Resonance Imaging in Crohn's Disease. **2022**, 12, 2533 1
- 64 Treatment and biologic maintenance-dosing patterns among pediatric patients with ulcerative colitis or Crohn's disease. 1-19 0
- 63 Development of a multimodal machine-learning fusion model to non-invasively assess ileal Crohn's disease endoscopic activity. **2022**, 107207 0
- 62 Diagnosis and Monitoring of Ulcerative Colitis. 0
- 61 Association between socioeconomic status and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study. **2022**, 9, e001000 0
- 60 Incidence, management and outcomes of very early onset inflammatory bowel diseases and infantile-onset disease: an epi-IIRN study. **2022**, 0
- 59 Technological advances in inflammatory bowel disease endoscopy and histology. 9, 0
- 58 Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. 0
- 57 Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-to-moderate ulcerative colitis. 0
- 56 Hypoxic mesenchymal stem cell-derived exosomes alleviate ulcerative colitis injury by limiting intestinal epithelial cells reactive oxygen species accumulation and DNA damage through HIF-1 $\alpha$  **2022**, 113, 109426 0
- 55 The treatment of inflammatory bowel disease with monoclonal antibodies in Asia. **2023**, 157, 114081 0
- 54 Factors Associated With Fecal Calprotectin Sample Collection Compliance: An IBD Center Quality Improvement Project. **2022**, 4, 0
- 53 Usefulness of Texture and Color Enhancement Imaging (TXI) in Assessing Mucosal Healing in Patients with Ulcerative Colitis. **2022**, 0
- 52 Magnetic resonance enterocolonography for assessing inflammation activity in Crohn's disease using the CDMI and MEGS indices. **2022**, 21, 39-48 0
- 51 How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?. *flgastro*-2022-102309 0
- 50 Inflammatory bowel disease cross-sectional imaging: What's new?. **2022**, 10, 1179-1193 1
- 49 Treat-to-target and sequencing therapies in Crohn's disease. **2022**, 10, 1121-1128 1

- 48 Therapeutic Drug Monitoring in Practice for Inflammatory Bowel Disease. **2022**, 24, 191-200 ○
- 47 Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study. **2022**, 22, ○
- 46 Medical Treatment Options for Ulcerative Colitis. ○
- 45 Cost per responder for vedolizumab and ustekinumab in Crohn's disease patients after failure of TNF-inhibitors in Italy. 10, 13-21 ○
- 44 Enteral Nutrition Prescription in Children and Adults with Inflammatory Bowel Diseases: Gaps in Current Gastroenterology Practice in Saudi Arabia. **2023**, 15, 232 ○
- 43 Treatment with adalimumab 80 mg every other week in inflammatory bowel disease: Results of treatment intensification in clinical practice. ○
- 42 Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. ○
- 41 Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis. ○
- 40 Bifidobacterium longum CCFM1206 Promotes the Biotransformation of Glucoraphanin to Sulforaphane That Contributes to Amelioration of Dextran-Sulfate-Sodium-Induced Colitis in Mice. **2023**, 71, 1100-1112 ○
- 39 Effects of the Antioxidant Quercetin in an Experimental Model of Ulcerative Colitis in Mice. **2023**, 59, 87 ○
- 38 Validation of red dichromatic imaging score (RDI score) to evaluate the severity of ulcerative colitis. ○
- 37 Role of MR enterography versus ileo-colonoscopy in the assessment of inflammatory bowel diseases. **2023**, 54, ○
- 36 Management of inflammatory bowel disease in the elderly: A review. **2023**, ○
- 35 A new Digital Health Program for Patients with Inflammatory Bowel Disease: Preliminary Program Evaluation (Preprint). ○
- 34 Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn's Disease. **2023**, 12, 2696 ○
- 33 The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. **2023**, 8, 458-492 ○
- 32 Association of genetic polymorphism of NUDT15, TPMT and ITPA gene in the toxicity and efficacy of azathioprine-based regimen in Egyptian inflammatory bowel disease patients. **2023**, 12, ○
- 31 Assessing the Relationship between the Gut Microbiota and Inflammatory Bowel Disease Therapeutics: A Systematic Review. **2023**, 12, 262 ○

- 30 Treatment escalation and de-escalation decisions in Crohn's disease: Delphi consensus recommendations from Japan, 2021. **2023**, 58, 313-345 ○
- 29 Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study. **2023**, 16, 175628482311512 ○
- 28 Distal Fecal Wash Host Transcriptomics Identifies Inflammation Throughout the Colon and Terminal Ileum. **2023**, ○
- 27 Editorial: treat-to-target in ulcerative colitis clinical management—small price to pay? Authors' reply. **2023**, 57, 571-572 ○
- 26 The Role of Artificial Intelligence in Monitoring Inflammatory Bowel Disease—The Future Is Now. **2023**, 13, 735 ○
- 25 Mucosal healing and inflammatory bowel disease: Therapeutic implications and new targets. 29, 1157-1172 ○
- 24 Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis. Volume 15, 125-138 ○
- 23 Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials. ○
- 22 Repeated and multiple fecal microbiota transplantations plus partial enteral nutrition as the first-line treatment in active pediatric Crohn's disease. 13, ○
- 21 Intestinal complications in Brazilian patients with ulcerative colitis treated with conventional therapy between 2011 and 2020. 29, 1330-1343 ○
- 20 Clinical Indices for Pediatric Inflammatory Bowel Disease Research. **2023**, 653-670 ○
- 19 Endoscopy and Inflammatory Bowel Disease. **2023**, 267-291 ○
- 18 Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review. **2023**, 11, 747 ○
- 17 Ulcerative colitis (K51), adults. **2023**, 22, 10-44 ○
- 16 Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. 29, 1395-1406 ○
- 15 Replacing Endoscopy with Magnetic Resonance Enterography for Mucosal Activity Assessment in Terminal Ileal Crohn's Disease: Are We There Yet?. **2023**, 13, 1061 ○
- 14 Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies. 29, 1539-1550 ○
- 13 Serum Bile Acid Metabolites Predict the Therapeutic Effect of Mesalazine in Patients with Ulcerative Colitis. **2023**, 22, 1287-1297 ○

- 12 Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study. **2023**, 16, 175628482311541 ○
- 11 The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer. **2023**, 12, 2432 ○
- 10 Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease. **2023**, 12, 2452 ○
- 9 Impaired Intestinal Permeability Assessed by Confocal Laser Endomicroscopy: A New Potential Therapeutic Target in Inflammatory Bowel Disease. **2023**, 13, 1230 ○
- 8 Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease. 1-8 ○
- 7 Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis. Publish Ahead of Print, ○
- 6 Ultrasonographic Transmural healing in Crohn's disease. **2023**, Publish Ahead of Print, ○
- 5 Maladies inflammatoires chroniques intestinales: scores et optimisation des comptes rendus anatomopathologiques. **2023**, ○
- 4 Can we change the natural course of inflammatory bowel disease?. **2023**, 16, 175628482311631 ○
- 3 Super Carbonate Apatite-miR-497a-5p Complex Is a Promising Therapeutic Option against Inflammatory Bowel Disease. **2023**, 16, 618 ○
- 2 Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN. ○
- 1 Video Capsule Endoscopy Plays an Important Role in the Management of Crohn's Disease. **2023**, 13, 1507 ○